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Summary 
 
Human cells maintain lipid homeostasis by regulated cleavage of membrane-
bound transcription factors, so-called sterol-regulatory element-binding 
proteins (SREBPs). The mature forms of SREBP-1 and -2 are transcriptional 
activators of lipogenic genes controlling cholesterol, fatty acids, and 
triglyceride biosynthesis and uptake. As the SREBPs play a central role in the 
regulation of the lipoprotein metabolism, we supposed that specific sequence 
variations, which correspond to single-nucleotide polymorphisms in these 
genes, and certain drugs, that influence the expression of SREBP, may result 
in alterations in plasma lipoprotein concentrations. 
A syndrome characterized by hypertriglyceridemia, hypercholesterolemia, 
hyperinsulinemia and lipodystrophy has been found to be associated with 
antiretroviral treatment (ART) including protease inhibitors. A marker 
predicting this syndrome has been identified in the gene encoding the sterol-
regulatory element-binding protein-1c (SREBP-1c), a regulator of 
triglycerides, cholesterol, insulin and adipocytes. A possible inhibition of 
SREBP-1c-dependent genes by the protease inhibitor indinavir and its 
possible reversal by the lipid-lowering drug simvastatin were studied in cell 
culture. The effects of indinavir and simvastatin on SREBP-1c-dependent 
genes were compared with the effects of indinavir and simvastatin on SREBP-
1c-independent genes. In fact, indinavir inhibited the SREBP-1c-dependent 
genes encoding the lipoprotein lipase and the fatty acid synthase in a dose-
dependent manner but not the SREBP-1c-independent gene encoding the 
low-density lipoprotein receptor. Furthermore, simvastatin antagonized the 
indinavir-induced SREBP-1c-inhibition. Thus, indinavir inhibits important 
effector genes of the SREBP-1c pathway, which may explain major 
antiretroviral treatment-related adverse effects. 
A single-nucleotide polymorphism (3'322C/G SNP) identified in the sterol-
regulatory element-binding protein-1c (SREBP-1c) gene was predictive of 
highly active antiretroviral therapy-related hyperlipoproteinemia. Increases in 
cholesterol, triglyceride and insulin were less frequently associated with 
homozygous SREBP-1c-3'322G (genotype 22) than with 
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heterozygous/homozygous SREBP-1c-3'322C (genotypes 11/12). The 
differences in messenger RNA conformation can explain the pharmacogenetic 
basis of these findings. The mRNA stability of both homozygous genotypes of 
SREBP-1c-3’322C/G was compared in the stably transfected T-REx cell lines 
using a real-time quantitative polymerase chain reaction method. The mRNA 
of the SREBP-1c-3’322C isoform (genotype 11) was shown to have a more 
abundance decay rate than 3’322G isoform (genotype 22). Thus, the 
sequence variation (3’322C/G SNP) in the coding 3’ end of the gene affects 
the secondary structure of the SREBP-1c mRNA, influences its degradation 
rate and, therefore, causes differences in the regulation of SREBP-1c 
expression. 
In the process of this thesis, three new splice variants of the human SREBP-1 
gene that shared different combinations of the SREBP-1a and -1c exons at 
the 3’ end of mRNA were identified. The splice variant containing exons 17, 
18a and 18c was designated as SREBP-1d, the splice variant containing 
exons 17, 18a, 18c and 19c was termed as SREBP-1e, and the splice variant 
containing exons 17, 18c and 20f was named as SREBP-1f. Analysis of tissue 
distribution showed that the new splice variants SREBP-1e and -1d were 
ubiquitously found in various human tissues and tumor-derived cells, whereas 
wild-type SREBP-1c and SREBP-1f transcripts were relatively tissue-specific. 
This high abundance led us to the hypothesis that splice variants SREBP-1e 
and SREBP-1d play a more general role in regulating cellular lipid levels as 
compared to other isoforms. 
This thesis concludes that the sterol-regulatory element-binding protein 
(SREBP)-1c is crucial in the metabolic side-effects associated with highly 
active antiretroviral therapy using protease inhibitors. Moreover, regulation 
mechanism  mediated by the transcription factor SREBP-1 is a model of a 
complex gene regulation system composed of different related levels: 
promoter regulation of effector genes, differences in mRNA stability and tissue 
specific splice variants in different quantities. 
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I. Introduction 
 
I.1. Molecular characterization of sterol-regulatory element-binding 
proteins (SREBPs) 
 
Mammalian cells maintain their cholesterol content within a narrow range by 
controlling the rate of intracellular de novo cholesterol biosynthesis and the 
amount of cholesterol obtained from extracellular lipoproteins by receptor-
mediated endocytosis (Brown and Goldstein, 1997; Wang et al., 1994). 
Cholesterol can be taken up with the diet (exogenous pathway) or can be 
synthesized de novo (endogenous pathway). In mammals, cholesterol is 
mainly synthesized in the liver and in the intestinal mucosa. Apart from 
biosynthesis and receptor-mediated endocytosis, cholesterol homeostasis is 
also regulated by the rate of intestinal absorption and catabolic degradation in 
the liver (Chawla et al., 2001). Further important physiological functions of 
cholesterol, especially for higher vertebrates, consist of its precursor role for 
the biosynthesis of, both, steroid hormones and bile acids. In eukaryotes, 
cholesterol is the main modulator of membrane fluidity and hence regulates 
phase transitions within the membrane (Bloch, 1983; Yeagle, 1985).  
Animal cells regulate their biosynthetic pathways so as to produce the 
required amounts of end-products but, to prevent intracellular over-
accumulation. An excess of intracellular cholesterol must be avoided as it 
forms toxic crystals whereas excess plasma cholesterol is deposited in 
arteries, initiating and accelerating atherosclerosis (Small and Shipley, 1974). 
End-product regulation of the cholesterol metabolism is achieved 
predominantly through transcriptional repression of genes that govern the 
synthesis of cholesterol and its receptor-mediated uptake from plasma 
lipoproteins (Goldstein and Brown, 1990). The synthesis and uptake of 
cholesterol in animal cells require membrane-bound transcription factors 
designated sterol-regulatory element-binding proteins (SREBPs) (Briggs et 
al., 1993; Wang et al., 1993). 
SREBPs directly activate the expression of more than 30 genes dedicated not 
only to the synthesis and uptake of cholesterol, but also of fatty acids, 
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triglycerides, and phospholipids, as well as the NADPH cofactor required to 
synthesize these molecules (Brown and Goldstein, 1997; Goldstein et al., 
2002; Sakakura et al., 2001). In the liver, SREBPs regulate the production of 
lipids for export into the plasma as lipoproteins and into the bile as micelles 
(Sheng et al., 1995). 
 
I.1.1. Activation of SREBPs through proteolytic processing 
 
SREBPs belong to the basic helix-loop-helix–leucine zipper (bHLH-Zip) family 
of transcription factors, but they differ from other bHLH-Zip proteins in that 
they are synthesized as inactive precursors bound to the endoplasmic 
reticulum (ER) (Brown and Goldstein, 1997; Goldstein et al., 2002). Each 
SREBP precursor of about 1150 amino acids is organized into three domains: 
(a) an NH2-terminal domain of about 480 amino acids that contains the bHLH-
Zip region for binding DNA; (b) two hydrophobic transmembrane–spanning 
segments interrupted by a short loop of about 30 amino acids that projects 
into the lumen of the ER; and (c) a COOH-terminal domain of about 590 
amino acids that performs the essential regulatory function (Figure 1). 
 
 
 
Figure 1. Domain structures of human SREBP-1a and SREBP-2. The sequence of 
SREBP-1c (not shown) is identical to that of SREBP-1a except for a shortened NH2-
terminal acidic domain (24 amino acids in SREBP-1c versus 42 amino acids in 
SREBP-1a) (Brown and Goldstein, 1997).  
 
In order to enter the nucleus and act as a transcription factor, the NH2-terminal 
domain of each SREBP must be released from the membrane proteolytically 
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(Figure 2). Three proteins required for SREBP processing have been 
delineated in cultured cells, using the tools of somatic cell genetics (Goldstein 
et al., 2002). One is an escort protein designated SREBP cleavage–activating 
protein (SCAP). The other two are proteases, designated Site-1 protease 
(S1P) and Site-2 protease (S2P). Newly synthesized SREBP is inserted into 
the membranes of the ER, where its COOH-terminal regulatory domain binds 
to the COOH-terminal domain of SCAP. SCAP is both an escort for SREBPs 
and a sensor of sterols. When cells become depleted in cholesterol, SCAP 
escorts the SREBP from the ER to the Golgi apparatus, where the two 
proteases reside. In the Golgi apparatus, S1P, a membrane-bound serine 
protease, cleaves the SREBP in the luminal loop between its two membrane-
spanning segments, dividing the SREBP molecule (Figure 2). The NH2-
terminal bHLH-Zip domain is then released from the membrane via a second 
cleavage mediated by S2P, a membrane-bound zinc metalloproteinase. The 
NH2-terminal domain, designated nuclear SREBP (nSREBP), enters the 
nucleus through nuclear lamin containing envelope (Caron et al., 2003) and 
activates transcription by binding to nonpalindromic sterol response elements 
(SREs) in the promoter/enhancer regions of multiple target genes. The binding 
of the NH2-terminal domain of SREBP to specific promoter elements results in 
an increase in the LDL receptor-mediated uptake of LDL particles from the 
plasma and in an increase in the endogenous cholesterol biosynthesis. 
When the cholesterol content of cells rises, SCAP senses the excess 
cholesterol through its membranous sterol-sensing domain, changing its 
conformation in such a way that the SCAP/SREBP complex is no longer 
incorporated into ER transport vesicles. The net result is that SREBPs lose 
their access to S1P and S2P in the Golgi apparatus, so their bHLH-Zip 
domains cannot be released from the ER membrane, and the transcription of 
target genes ceases (Horton et al., 2002). As a result, the synthesis of 
cholesterol and fatty acids declines.  
Very recently it has been found the new component of SREBP pathway - Insig 
proteins. Under conditions of sterol excess, the SCAP/SREBP complex binds 
to Insig, an intrinsic membrane proteins of the ER (Yang et al., 2002; Yabe et 
al., 2002). This binding prevents the SCAP/SREBP complex from being 
incorporated into transport vesicles. As a result, SREBPs remain trapped in 
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the ER, and proteolytic processing cannot occur. The nuclear content of 
SREBPs declines rapidly as a result of proteasomal degradation. As a result, 
the synthesis of cholesterol and fatty acids declines. This finding confirms the 
crucial role of the SCAP sterol-sensing domain and its interaction with the 
Insig proteins for the maintenance of cellular cholesterol homeostasis. 
 
 
 
Figure 2. Model for the sterol-mediated proteolytic release of SREBPs from 
membranes. SCAP is a sensor of sterols and escorts the SREBPs. When cells are 
depleted of sterols, SCAP transports SREBPs from the ER to the Golgi apparatus, 
where two proteases, Site-1 protease (S1P) and Site-2 protease (S2P), act 
sequentially to release the NH2-terminal bHLH-Zip domain from the membrane. The 
bHLH-Zip domain enters the nucleus and binds to a sterol response element (SRE) 
in the enhancer/promoter region of target genes, activating their transcription. When 
cellular cholesterol rises, the SCAP/SREBP complex is no longer incorporated into 
ER transport vesicles, SREBPs no longer reach the Golgi apparatus, and the bHLH-
Zip domain cannot be released from the membrane. As a result, transcription of all 
target genes declines (Horton et al., 2002). 
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When cholesterol is added to membrane vesicles in vitro, SCAP undergoes a 
conformational change as revealed by its differential sensitivity to proteolytic 
digestion (Brown et al., 2002). The correlation between this cholesterol-
induced conformational change in vitro, and the binding of SCAP and the 
Insig proteins in vivo, indicates the possibility that the interaction between the 
two proteins requires SCAP to be in a conformation that depends on the 
presence or absence of specific lipids in the bilayer. The conformational 
change in SCAP could be secondary to the cholesterol-induced interaction 
between the Insig proteins and the SCAP sterol-sensing domain. 
These results indicate a mechanism by which a conformational change in the 
sterol-sensing domain of SCAP converts information about the physical 
properties of membranes into an action that governs the transcription of 
genes with end products that ultimately alter the membrane composition. 
 
I.1.2. The isoforms of SREBP 
 
The mammalian genome encodes three SREBP isoforms, designated 
SREBP-1a, SREBP-1c, and SREBP-2. SREBP-2 is encoded by a gene on 
human chromosome 22q13. Both SREBP-1a and -1c are derived from a 
single gene on human chromosome 17p11.2 through the use of alternative 
transcription start sites that produce alternate forms of exon 1, designated 1a 
and 1c (Brown and Goldstein, 1997). SREBP-1a is a potent activator of all 
SREBP-responsive genes, including those that mediate the synthesis of 
cholesterol, fatty acids, and triglycerides. High-level transcriptional activation 
is dependent on exon 1a, which encodes a longer acidic transactivation 
segment than does the first exon of SREBP-1c. The roles of SREBP-1c and 
SREBP-2 are more restricted than that of SREBP-1a. SREBP-1c preferentially 
enhances transcription of genes required for fatty acid synthesis but not 
cholesterol synthesis. Like SREBP-1a, SREBP-2 has a long transcriptional 
activation domain, but it preferentially activates cholesterol synthesis (Brown 
and Goldstein, 1997). SREBP-1a and SREBP-2 are the predominant isoforms 
of SREBP in most cultured cell lines, whereas SREBP-1c and SREBP-2 
predominate in the liver and most other intact tissues (Shimomura et al., 
1997a).  
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When expressed at higher than physiologic levels, each of the three SREBP 
isoforms can activate all enzymes which used to generate cholesterol and 
fatty acids. However, at normal levels of expression, SREBP-1c favors the 
fatty acid biosynthetic pathway and SREBP-2 favors cholesterologenesis. 
SREBP-2–responsive genes in the cholesterol biosynthetic pathway include 
those for the enzymes HMG-CoA synthase (Smith et al., 1988), HMG-CoA 
reductase (Reynolds et al., 1984), farnesyl diphosphate synthase (Ericsson et 
al., 1996), and squalene synthase (Guan et al., 1995). SREBP-1c–responsive 
genes include those for ATP citrate lyase (which produces acetyl-CoA) 
(Shimano et al., 1999), acetyl-CoA carboxylase (Lopez et al., 1996), fatty acid 
synthase (Bennett et al., 1995) and lipoprotein lipase (Shimomura et al., 
1998). Other SREBP-1c target genes encode a rate-limiting enzyme of the 
fatty acid elongase complex, which converts palmitate to stearate (Moon et al., 
2001); stearoyl-CoA desaturase, which converts stearate to oleate; and 
glycerol-3-phosphate acyltransferase, the first committed enzyme in 
triglyceride and phospholipid synthesis (Edwards et al., 2000). Finally, 
SREBP-1c and SREBP-2 activate genes required to generate NADPH, which 
is consumed at multiple stages in these lipid biosynthetic pathways 
(Shimomura et al., 1998a). 
 
I.1.3. Function of individual SREBP isoforms in vivo 
 
To study the functions of individual SREBPs in the liver, transgenic mice 
overexpressing truncated versions of SREBPs (nSREBPs) that terminate prior 
to the membrane attachment domain have been produced. These nSREBPs 
enter the nucleus directly, bypassing the sterol-regulated cleavage step. By 
studying each nSREBP isoform separately, it was determined their distinct 
activating properties, albeit when overexpressed at nonphysiologic levels. 
Overexpression of nSREBP-1c in the liver of transgenic mice produces a 
triglyceride-enriched fatty liver with no increase in cholesterol (Shimano et 
al.1997a). mRNAs for fatty acid synthetic enzymes and rates of fatty acid 
synthesis are elevated fourfold in this tissue, whereas the mRNAs for 
cholesterol synthetic enzymes and the rate of cholesterol synthesis are not 
increased (Shimomura et al., 1998a). Conversely, overexpression of 
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nSREBP-2 in the liver increases the mRNAs encoding all cholesterol 
biosynthetic enzymes; the most dramatic is a 75-fold increase in HMG-CoA 
reductase mRNA (Horton et al., 1998). mRNAs for fatty acid synthesis 
enzymes are increased to a lesser extent, consistent with the in vivo 
observation that the rate of cholesterol synthesis increases 28-fold in these 
transgenic nSREBP-2 livers, while fatty acid synthesis increases only fourfold. 
This increase in cholesterol synthesis is even more remarkable when one 
considers the extent of cholesterol overload in this tissue, which would 
ordinarily reduce SREBP processing and essentially abolish cholesterol 
synthesis.  
The consequences of overexpressing SREBP-1a, which is expressed only at 
low levels in the livers of adult mice, rats, hamsters, and humans have also 
been studied (Shimomura et al., 1997a). nSREBP-1a transgenic mice develop 
a massive fatty liver engorged with both cholesterol and triglycerides 
(Shimano et al., 1996), with heightened expression of genes controlling 
cholesterol biosynthesis and, still more dramatically, fatty acid synthesis. The 
preferential activation of fatty acid synthesis (26-fold increase) relative to 
cholesterol synthesis (fivefold increase) explains the greater accumulation of 
triglycerides in their livers.  
Considered together, the overexpression studies indicate that both SREBP-1 
isoforms show a relative preference for activating fatty acid synthesis, 
whereas SREBP-2 favors cholesterol.  
Knockout mice that lack all nSREBPs die early in embryonic development. 
For instance, a germline deletion of S1P, which prevents the processing of all 
SREBP isoforms, results in death before day 4 of development (Yang et al., 
2001; Mitchell et al., 2001). Germline deletion of SREBP-2 leads to 100% 
lethality at a later stage of embryonic development than does deletion of S1P 
(embryonic day 7–8). In contrast, germline deletion of SREBP-1, which 
eliminates both the 1a and the 1c transcripts, leads to partial lethality, in that 
about 15–45% of SREBP-1–/– mice survive (Shimano et al., 1997a). The 
surviving homozygotes manifest elevated levels of SREBP-2 mRNA and 
protein, which presumably compensates for the loss of SREBP-1a and -1c. 
When the SREBP-1c transcript is selectively eliminated, no embryonic 
lethality is observed, suggesting that the partial embryonic lethality in the 
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SREBP-1–/– mice is due to the loss of the SREBP-1a transcript (Liang et al., 
2002). 
The studies in genetically manipulated mice clearly show that, as in cultured 
cells, SCAP and S1P are required for normal SREBP processing in the liver. 
SCAP, acting through its sterol-sensing domain, mediates feedback regulation 
of cholesterol synthesis. 
The SREBPs play related but distinct roles: SREBP-1c, the predominant 
SREBP-1 isoform in adult liver, preferentially activates genes required for fatty 
acid synthesis, while SREBP-2 preferentially activates the LDL receptor gene 
and various genes required for cholesterol synthesis. SREBP-1a and SREBP-
2, but not SREBP-1c, are required for normal embryogenesis. 
 
I.1.4. Transcriptional regulation of SREBP genes 
 
Regulation of SREBPs occurs at two levels - transcriptional and 
posttranscriptional. The posttranscriptional regulation discussed above 
involves the sterol-mediated suppression of SREBP cleavage, which results 
from sterol-mediated suppression of the movement of the SCAP/SREBP 
complex from the ER to the Golgi apparatus (Figure 2). This form of regulation 
is manifest not only in cultured cells (Brown and Goldstein, 1997), but also in 
the livers of rodents fed cholesterol-enriched diets (Shimomura et al., 1997).  
The transcriptional regulation of the SREBPs is more complex. SREBP-1c 
and SREBP-2 are subject to distinct forms of transcriptional regulation, 
whereas SREBP-1a appears to be constitutively expressed at low levels in 
liver and most other tissues of adult animals (Shimomura et al., 1997a). One 
mechanism of regulation shared by SREBP-1c and SREBP-2 involves a feed-
forward regulation mediated by SREs present in the enhancer/promoters of 
each gene (Sato et al., 1996; Amemiya-Kudo et al., 2000). Through this feed-
forward loop, nSREBPs activate the transcription of their own genes. In 
contrast, when nSREBPs decline, as in SCAP or S1P knockout mice, there is 
a secondary decline in the mRNAs encoding SREBP-1c and SREBP-2 
(Matsuda et al., 2001; Yang et al., 2001). 
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I.1.5. SREBPs in metabolic disorders and human disease  
 
Many individuals with obesity and insulin resistance also have fatty livers, one 
of the most commonly encountered liver abnormalities (Marchesini et al., 
2001). A subset of individuals with fatty liver go on to develop fibrosis, 
cirrhosis, and liver failure. Evidence indicates that the fatty liver of insulin 
resistance is caused by SREBP-1c, which is elevated in response to the high 
insulin levels (Shimomura et al., 1999a).  
The incidence of coronary artery disease increases with increasing plasma 
LDL-cholesterol levels, which in turn are inversely proportional to the levels of 
hepatic LDL receptors. SREBPs stimulate LDL receptor expression, but they 
also enhance lipid synthesis (Brown and Goldstein, 1997), so their net effect 
on plasma lipoprotein levels depends on a balance between opposing effects 
(Figure 3).  
 
 
Figure 3. SREBP as a transcriptional enhancer of genes involved in the cholesterol 
uptake and biosynthesis. As the intracellular cholesterol concentration decreases, the 
active forms of the SREBPs bind to the sterol-regulatory elements (SREs) at the low-
density lipoprotein (LDL) receptor promoter region and activate the LDL receptor 
gene (Südhof et al., 1987). Consequently, the number of LDL receptor molecules 
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available at the cell surface and thus, the receptor-mediated uptake of cholesterol-
containing LDL particles increase. On the other hand, the SREBPs bind also to the 
promoters of genes involved in cholesterol synthesis and activate these genes. After 
administration of statins, the SREBP mediate the increase in the LDL receptor-
mediated cholesterol uptake. The parallel SREBP-mediated increase in the 
cholesterol synthesis is inhibited by HMG-CoA reductase inhibitors, so the net effect 
of statins administration is a decrease in the plasma LDL cholesterol concentration. 
 
The lowering of serum cholesterol is increasingly recognized as essential in 
the prevention of coronary heart disease and other atherosclerotic disease 
(Hebert et al., 1997). A class of widely used cholesterol-lowering drugs, the 
hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also 
called statins, inhibit the rate-limiting enzyme of the intracellular cholesterol 
synthesis, the HMG-CoA reductase (Garg and Grundy, 1988). 
As has been outlined before, SREBPs play a central role in the regulation of 
the lipoprotein metabolism. Therefore specific sequence variations (e.g. 
corresponding to single-nucleotide polymorphisms) in the genes encoding the 
SREBPs and certain drugs, that influence the expression of SREBP, may 
result in alterations in plasma lipoprotein concentrations. Recently it has been 
reported that single-nucleotide polymorphisms in the SREBP-2 (A595G; 
R371K) and SREBP-1a (-36del/G) genes influence lipid parameters and the 
risk of coronary atherosclerosis (Muller and Miserez, 2002; Miserez et al., 
2002; Vedie et al., 2001).  
In this thesis we focussed on specific sequence variation of the human 
SREBP-1c gene and its influence on lipoprotein metabolism. We also 
analyzed the expression of major mediator genes of the lipid homeostasis 
upon administration of the HIV-protease inhibitor indinavir and explain the 
putative molecular mechanisms responsible for these adverse effects. 
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I.2. The role of SREBP-1c in drug induced hyperlipidaemia 
 
I.2.1. The effects of HIV-protease inhibitor indinavir on SREBP-1c 
 
In the recent years antiretroviral treatment (ART) including protease inhibitors 
(PIs) has drastically lowered morbidity and immediate mortality in HIV-1-
infected patients (Egger et al., 1997; Palella et al., 1998). Currently, the 
recommended therapy for such patients includes the use of one or two HIV 
protease inhibitors (PIs) combined with two nucleoside reverse transcriptase 
inhibitors (NRTIs) or two nucleoside RTIs combined with one non-nucleoside 
reverse transcriptase inhibitor (NNRTI) (Carpenter et al., 2000). Inhibition of 
the HIV protease prevents cleavage and maturation of the viral polyprotein 
precursor leading to production of non-infectious viral particles (Flexner, 
1998). The HIV reverse transcriptase is required to copy the viral RNA 
genome and inhibitors used to target this enzyme consist of non-nucleoside, 
non-competitive inhibitors or chain-terminating nucleoside analogues (Beach, 
1998). 
The problem of this highly active antiretroviral therapy is the development of 
hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia and 
lipodystrophy (Carr et al., 1998; Carr et al., 1999). Thus, PIs, although 
drastically lowering immediate morbidity and mortality, may increase the risk 
of cardiovascular complications (Henry et al., 1998; Périard et al., 1999). 
Recent studies revealed that ART-related adverse effects are common and 
persist in patients remaining on treatment (Carr et al., 1998, Périard et al., 
1999). 
The recent experiments show that sterol-regulatory element-binding protein -1 
(SREBP-1), a transcription factor known to promote lipogenic gene 
expression, could be involved in this process. Dowell et al. observed that 
several HIV protease inhibitors inhibited preadipocyte differentiation and 
promote adipocyte cell death. The level of the proteolytically processed, active 
form of sterol-regulatory element-binding protein-1 was also reduced markedly 
in nelfinavir-treated cells, whereas the level of the precursor form of this 
protein was unaffected (Dowell et al., 2000). The results of Caron et al. show 
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that indinavir inhibit the adipocyte differentiation program of preadipocytes at 
an early step and impairs SREBP-1 intranuclear localization in cultured cells. 
The molecular mechanism of these clinical and biological alterations is 
currently unknown but it is probably multifactorial (Caron et al., 2001). 
To investigate the molecular basis responsible for these adverse effects, we 
firstly determined whether the key regulators of lipid homeostasis, SREBP-1c 
or SREBP-2, may be involved. Reporter gene assays with major effector 
genes of lipid metabolism were performed. To show a potential association 
the effect of the PI indinavir on SREBP-1c and the consequences of a 
possible inhibition was determined. Effector genes specifically activated by 
SREBP-1c in cell culture in the presence of indinavir were studied. 
Additionally the possible reversal by the lipid-lowering drug simvastatin was 
investigated. Finally, the effects of indinavir and simvastatin on the 
inhibition/activation of SREBP-1c-dependent genes were compared with the 
effects of indinavir and simvastatin on the SREBP-1c-independent genes. 
 
I.2.2. The role of single-nucleotide polymorphism in SREBP-1c gene in 
protease inhibitor-induced hyperlipoproteinemia  
 
Recent studies revealed that adverse effects (hyperlipoproteinemia, insulin 
resistance and lipodystrophy) of antiretroviral treatment (ART) affect only a 
part of the subjects treated with PIs (Carr et al., 1999; Segerer et al., 1999; 
Carr, 2000). Therefore, the presence of subjects without any increase in 
plasma lipoprotein concentrations or insulin resistance and diabetes mellitus, 
and of others with striking increases in lipoproteins and insulin suggests an 
underlying genetic predisposition to this syndrome. 
Miserez et al. recently demonstrated that genetic variants of the sterol-
regulatory element-binding protein-1c, also called adipocyte determination 
and differentiation factor 1 (SREBP-1c/ADD-1), can modify plasma cholesterol 
and triglyceride levels. After identification of a frequent single-nucleotide 
polymorphism (SNP), 3’322C/G, in the SREBP-1c gene, it was demonstrated 
that this inherited SNP predicts the development of PI-associated 
hyperlipoproteinemia. This single-nucleotide polymorphism does not alter the 
amino acid sequence. The frequency of SREBP-1c-3’322C homozygosity 
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(genotype 11) was 40.3%, SREBP-1c-3’322C/SREBP-1c-3’322G 
heterozygosity (genotype 12) 45.6%, and SREBP-1c-3’322G homozygosity 
(genotype 22) 14.1%, resulting in a high polymorphism information content 
value of 0.37. Increases in cholesterol were less frequently associated with 
homozygous SREBP-1c-3’322G (genotype 22) than with 
heterozygous/homozygous SREBP-1c-3’322C (genotypes 11/12) and 
correlated with leptin and insulin increases, particularly in genotype 11/12 
carriers (Miserez et al., 2001; Dorenbaum and Miserez, 2001). 
To further investigate the molecular basis of these SNP-associated 
differences, we first excluded the possibility that SREBP-1c-3’322G causes 
alternative splicing and used computer-based analyses to predict differences 
in the putative mRNA secondary structure (SREBP-1c-3’322C versus 
SREBP-1c-3’322G). Furthermore, synonymous mutations, such as SREBP-
1c-3’322C/G, cannot be a priori considered as neutral or non-pathogenic, 
because they may directly affect mRNA structure and/or stability (Richard and 
Beckmann, 1995). This finding is particularly important because it has been 
demonstrated that the SREBP-1c pathway is regulated not only by cleavage 
activation but also by rate of mRNA degradation (Xu et al., 1999; Xu et al., 
2001). 
As the expression of the SREBP-1c gene can be regulated at the mRNA 
level, other specific sequence variations (3’322C/G SNP) could affect the 
secondary structure of the SREBP-1c mRNA and influence its degradation 
rate additionally. A possible association between the mRNA stability of the 
SREBP-1c gene in the presence of a single-nucleotide polymorphism 
3’322C/G was determined in vitro. For that, the mRNA stability of both 
homozygous genotypes of SREBP-1c-3’322C/G was compared in the stably 
transfected T-REx cell lines using a real time quantitative polymerase chain 
reaction method. 
 
I.3. Alternative splicing of human SREBP-1 
 
The protein coding sequences of most eukaryotic messenger RNA precursors 
(pre-mRNAs) are interrupted by non-coding sequences called introns. Pre-
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mRNA splicing is the process by which introns are removed and the protein 
coding elements assembled into mature mRNAs. Alternative pre-mRNA 
splicing selectively joins different protein coding elements to form mRNAs that 
encode proteins with distinct functions, and is therefore an important source of 
protein diversity (Maniatis and Tasic, 2002). The proteome of a cell can 
rapidly change in response to extracellular stimuli through complex signal-
transduction pathways. Changes in protein composition can be regulated at 
many different levels: transcription, post-translational protein modification and 
inducible alternative pre-mRNA splicing. A recent study estimated that greater 
than 55% of human genes are alternatively spliced (Kan et al., 2001). 
Although a number of different factors that affect splicing have been identified, 
the molecular mechanisms of alternative pre-mRNA splicing remain poorly 
defined (Maniatis and Tasic, 2002). 
Sterol-regulatory element-binding protein-1 (SREBP-1) belongs to the family 
of the basic/helix-loop-helix/leucine zipper transcription factors. They have 
emerged as a major factor involved in the fatty acid, phospholipids, 
triglycerides and insulin regulation (Horton et al., 2002). Both SREBP-1a and -
1c isoforms are derived from a single gene on human chromosome 17p11.2 
through the use of alternative splicing at both the 5’ and the 3’ ends of the 
mRNA. The gene spans 26 kb and encodes 22 exons and 20 introns. Exons 
1a and 1c are transcribed from different promoters using two alternative 
transcription start sites and spliced to a common exon 2. Exons 2-17 have 
been found in all SREBP-1 cDNAs (Hua et al., 1995). SREBP-1a and 
SREBP-1c differ in sequence at both of their 5’ and 3’ ends. Splice variants 
SREBP-1a and -1c are different in exons 1, 18 and 19 (Figure 4). One full-
length human cDNA contained the c sequences on both ends and was 
designated SREBP-1c. The rat homologue of SREBP-1c, named ADD1 
(adipocyte differentiation and determination factor one), was cloned 
independently as a protein which binds to E-boxes, and presumably promotes 
adipocyte differentiation (Tontonoz et al., 1993). A full-length cDNA isolated 
from Chinese hamster ovary (CHO) cells contained the a sequences on both 
ends and was named SREBP-1a (Sato et al., 1994). A cDNA containing the a 
sequence on the 5’ end and the c sequence on 3’ end was created artificially 
and was designated SREBP-1b (Yokoyama et al., 1993). 
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Figure 4. Alternative splicing of the SREBP-1 gene. The splicing patterns that 
produce three alternatively spliced transcripts, SREBP-1a, SREBP-1b and SREBP-
1c, are indicated. 
 
SREBP-1a is a potent activator of all SREBP-responsive genes, including 
those that mediate the synthesis of cholesterol, fatty acids, and triglycerides. 
High-level transcriptional activation is dependent on exon 1a, which encodes 
a longer acidic transactivation segment than does the first exon of SREBP-1c. 
SREBP-1c preferentially enhances transcription of genes required for fatty 
acid synthesis but not cholesterol synthesis. SREBP-1a is the predominant 
isoform of SREBP in most cultured cell lines, whereas SREBP-1c 
predominates in the liver and most other tissues (Shimomura et al., 1997a). 
In the process of cloning the SREBP-1c gene we observed a number of 
different mRNA transcripts indicating possible alternative splicing of this gene 
in humans at the 3’ end of pre-mRNA. We analyzed these transcripts using 
reverse transcriptase (RT) experiments in human normal and tumor tissues, in 
lymphocytes from several patients, and, finally, identified them by sequencing. 
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III. Materials and Methods 
 
III.1. Materials 
 
III.1.1. Cell culture reagents and chemicals 
 
Cholesterol, 25-hydroxycholesterol, poly-D-lysine hydrobromide, lipoprotein-
deficient serum (LPDS), penicillin, streptomycin, actinomycin D and ethidium 
bromide were purchased from Sigma, St. Louis, MO, USA. Cell culture media 
supplements were obtained from Invitrogen (Invitrogen, Carlsbad, CA, USA). 
Agarose was obtained from Applichem (Applichem, Darmstadt, Germany). 
Indinavir sulfate and simvastatin were provided by Merck & Co. Inc., Rahway, 
New Jersey, USA. The inactive lactone prodrug simvastatin was converted 
into its active dihydroxy-open form (L-644128) by acidic hydrolysis according 
to the manufacturer's protocol. Aqueous solutions of indinavir sulfate and the 
active dihydroxy-open form of simvastatin were prepared. All other chemicals 
used were of best quality available and were purchased from Merck (Merck, 
Darmstadt, Germany), Sigma or Fluka (Fluka, Buchs, Switzerland). 
 
III.1.2. Buffers 
 
Buffers were purchased from Invitrogen. 
Name Composition 
TAE buffer 50x 
TBE buffer 10x 
TE buffer 1x 
2 M Tris/acetate, pH 8.5, 50 mM EDTA 
1 M Tris, 0.9 M Boric acid, 10 mM EDTA, pH 8.4 
10 mM Tris/HCl, pH 8.0, 1 mM EDTA 
 
 
III.1.3. PCR primers and oligonucleotides 
 
Primers were obtained from Microsynth (Microsynth, Balgach, Switzerland). 
Name Sequence 
GAPDH F primer 5’-ACATCATCCCTGCCTCTACTGG-3’ 
GAPDH R primer 5’-AGTGGGTGTCGCTGTTGAACTC-3’ 
FAS F primer 5’-GGAGGTACCGCGTTCCTTGTGCTCCAGCGCGC-3’ 
FAS R primer 5’-CCCAAGCTTCGCGTCCCTCTGGAGGAGCTG CAA G-3’ 
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LDLR F primer 5'-AGCTGGTACCCGGAGACCCAAATACAACA-3' 
LDLR R primer 5'-TGTCCAAGCTTGAAACCCTGGCTTCCCGCGA-3' 
LPL F primer 5’-GGGGTACCTGCAGGAGTATTCTATATAAGATAG-3’ 
LPL R primer 5’-CCCAAGCTTCGCGTCCCTCTGGAGGAGCTGCAAG-3’ 
SREBP-1c primer F 5’-CCCAAGCTTGGAGGGGTAGGGCCAACGGCCTGGAC-3’ 
SREBP-1c primer R 5’-CCGCTCGAGGTTTCTAAAAGATGTTTATTTTCCTTAAG-3’ 
SREBP-1c-3322C/G F 5’-CCCTCCCCCAGCACCTAGGGAAAGGCTTCCCCTCCCCC-3’ 
SREBP-1c-3322C/G R 5’-GGGGGAGGGGAAGCCTTTCCCTAGGTGCTGGGGGAGGG-3’ 
SREBP-1a primer F 5'-GATCTGGACGCGGCGCTGCTGACCGACATCG-3’ 
F ex 17 primer 5’-AGGCCCCAGGCTTCCGCCCTTGAGC-3’ 
R 3’UTR primer  5’-GGTGAGACGTGCCAGACTTCTTGCAG-3’ 
R ex 2 SREBP-1 5’-CATGGACGGGTACATCTTCAATGGAGTGG-3’ 
Random hexamer d(N)6 
 
III.2. Methods 
 
III.2.1. Cell culture 
 
III.2.1.1. Growth and maintenance of cell lines 
 
Human embryonic kidney (HEK) 293 and human hepatocellular carcinoma 
(HepG2) cells were maintained in Dulbecco's modified Eagle's medium 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen), 
100 units/ml penicillin, and 100 µg/ml streptomycin (Sigma). The confluent 
culture was splited 1:5 every 3 days using tripsin/EDTA solution, seeded into 
sterile culture flasks and cultured in an incubator at 37°C under 5% CO2 
atmosphere and saturated humidity. The cell lines were used at passage 
number 3-15 in all studies. 
 
III.2.1.2. Freezing and thawing of cultured cells 
 
For freezing only the early-passage cells were used. The freezing of multiple 
vials of the particular cell line ensure an adequate supply of early-passage 
cells. The cells were frozen in freezing medium (70% Dulbecco's modified 
Eagle's medium, 20% FBS, 10% DMSO) at a density of 5 x 106 cells/cryovial. 
Cryotubes were transferred into the freezing container (Nalgene, San Diego, 
CA, USA) and hold overnight at -70°C. For long storage, cryovials were 
transferred into liquid nitrogen.  
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For thawing the cryotube containing 5 x 106 cells/ml was removed from liquid 
nitrogen and thawed quickly at 37°C. Subsequently, the cells suspension was 
transferred to a sterile 50 ml Falcon tube (BD Falcon) containing 20 ml of 
complete medium and centrifuged for 10 minutes at 750 x g at room 
temperature to wash the DMSO away. The cells were resuspended in 25 ml 
fresh, complete medium, seeded on culture flasks and cultured in an 
incubator at 37°C under 5% CO2 atmosphere and saturated humidity until the 
cells were 80-90% confluent. 
 
III.2.2. Construction of plasmids 
 
III.2.2.1. Lipoprotein lipase reporter gene construct 
 
The pGL2-lipoprotein lipase (LPL) reporter gene construct contained 
nucleotides -1910 to -9 (A of the ATG translation start site was assigned +1 in 
all the constructs) of the LPL gene promoter (GenBank X68111; nucleotides 1 
to 1902 according to GenBank numbering), comprising three putative sterol-
regulatory elements. The promoter was amplified by polymerase chain 
reaction (PCR) using the oligonucleotide sequences 5’-GGG GTA CCT GCA 
GGA GTA TTC TAT ATA AGA TAG-3’ and 5’-CCC AAG CTT CGC GTC CCT 
CTG GAG GAG CTG CAA G-3’ (restriction sites are shown in bold), digested 
with Kpn I and Xho I (New England Biolabs, Beverly, MA, USA), purified with 
QIAquick purification kit (Qiagen, Valencia, CA, USA), and ligated using 
Takara ligation kit (Takara, Shiga, Japan) into the pGL2–Basic vector 
(Promega, Madison, WI, USA). 
 
III.2.2.2. Fatty acid synthase reporter gene construct  
 
The pGL2-fatty acid synthase (FAS) reporter gene construct contained 
nucleotides -1485 to -1246 of the FAS gene promoter (GenBank X54671; 
nucleotides 1381 to 1620 according to GenBank numbering), comprising the 
key regulatory elements such as the sterol-regulatory element. The promoter 
was cloned into pGL2 following PCR (5’-GGA GGT ACC GCG TTC CTT GTG 
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CTC CAG CGC GC-3’; 5’-CAG AAG CTT CTG  GAC GGG ACG CTG CTG 
CCG TCT CTC-3’) using Kpn I and Xho I restriction sites. 
 
III.2.2.3. Low-density lipoprotein receptor (LDLR) reporter gene 
construct 
 
The pGL2-LDLR-construct contained nucleotides -328 to -61 of the LDLR 
gene promoter (GenBank L29401; nucleotides 380 to 627 according to 
GenBank numbering), comprising one SRE. The promoter was cloned into 
pGL2 following PCR (5'-AGC TGG TAC CCG GAG ACC CAA ATA CAA CA-
3'; 5'-TGT CCA AGC TTG AAA CCC TGG CTT CCC GCG A-3') using Kpn I 
and Xho I restriction sites. 
 
III. 2.2.4. Cloning of human wild-type SREBP-1c 
 
Expression plasmid for human SREBP-1c was constructed by cloning full-
length coding sequences and the entire 3' untranslated region (3' UTR) of 
SREBP-1c using forward primer: 5’-CCC AAG CTT GGA GGG GTA GGG 
CCA ACG GCC TGG AC-3’ and reverse primer 5’-CCG CTC GAG GTT TCT 
AAA AGA TGT TTA TTT TCC TTA AG-3’ (restriction sites for Xho I and Hind 
III are shown in bold) from HeLa cDNA library. The amplicon was digested, 
purified, and ligated into the expression vector pcDNA3 (Invitrogen). 
Sequencing of SREBP-1c clones was done by Microsynth, single strand 
sequencing using vectors and internal sequencing primers. 
 
III. 2.2.5. Cloning of human SREBP-1c containing single-nucleotide 
polymorphism 3’322C/G; site-directed mutagenesis 
 
A plasmid pcDNA3 containing the wild-type SREBP-1c cDNA (pcDNA3-
SREBP-1c) was used as a template for site-directed mutagenesis. The 
sequence variant discovered (bold) was introduced by using the 
oligonucleotides SREBP-1c-3’322C/G - F primer: 5'-CCC TCC CCC AGC 
ACC TAG GGA AAG GCT TCC CCT CCC CC-3', SREBP-1c-3’322C/G - R 
primer (its inverse complementary sequence) and the QuikChange(TM) Site-
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Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA). Epicurian Coli XL1-
Blue supercompetent cells were transformed according to the instructions of 
the manufacturer. Fifty clones were PCR-amplified using primers homologous 
to exon 17 and 3’-untranslated region of SREBP-1c (F ex17 primer: 5’-AGG 
CCC CAG GCT TCC GCC CTT GAG C-3’ and R 3’UTR primer: 5’-GGT GAG 
ACG TGC CAG ACT TCT TGC AG-3’, respectively). The amplicons were 
digested with Xmn I (New England Biolabs) to confirm the presence of the 
sequence encoding 3’322G. Positive clones were sequenced. The modified 
region containing the sequence encoding 3’322G was cut out using Xho I and 
Bsu36 I (New England Biolabs) and ligated into the corresponding sites of the 
parental plasmid pcDNA3-SREBP-1c. The presence of the nucleotide 
substitution encoding the 3’322G isoform was again confirmed by sequencing 
(Microsynth). 
 
III. 2.2.6. Cloning of human alternative splice variant SREBP-1d 
 
Expression plasmid for human SREBP-1d was constructed by cloning the 3’-
region of coding sequences of SREBP-1 from a liver cDNA library. For PCR 
amplification the forward (F ex17) primer 5’-AGG CCC CAG GCT TCC GCC 
CTT GAG C-3’ and reverse (SREBP-1c R) primer 5’-CCG CTC GAG GTT 
TCT AAA AGA TGT TTA TTT TCC TTA AG-3’ (restriction site for Xho I is 
shown in bold) were used. The amplicon was digested using Xho I and Bsu36 
I restriction endonucleases (New England Biolabs), purified with QIAquick 
purification kit (Qiagen) and ligated into the corresponding sites of the 
expression vector pcDNA3-SREBP-1c.  
The 5’-end of the splice variant SREBP-1d was determined by polymerase 
chain reaction using two forward primers homologous to exon 1a (SREBP-1a 
F primer: 5'-GAT CTG GAC GCG GCG CTG CTG ACC GAC ATC G-3’) and 
exon 1c (SREBP-1c F primer: 5’-CCC AAG CTT GGA GGG GTA GGG CCA 
ACG GCC TGG AC-3’), and reverse primer homologous to exon 2 (R ex 2 
SREBP-1 primer: 5’-CAT GGA CGG GTA CAT CTT CAA TGG AGT GG-3’) 
which is specific for SREBP-1a and SREBP-1c. Liver cDNA library expressing 
only the SREBP-1d splice variant was used as a template. The polymerase 
chain reaction analysis revealed that the amplification occurs only when the 
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forward primer, homologous to exon 1c of the SREBP-1c isoform, was used. 
Therefore, the splice variant SREBP-1d contains at the 5’-end the exon 1c 
and the N-terminus of this splice variant is similar to the SREBP-1c isoform. 
 
III.2.2.7. Confirmation of constructs  
 
All constructs were confirmed by sequencing and contained sequences 
identical to those previously published and demonstrated to be functional 
(Schoonjans et al., 2000; Bennett et al., 1995; Shimano et al., 1997; Hua et 
al., 1993). In the reporter gene experiments, the regulatory sequences of the 
inserts have been demonstrated to be inhibited by sterols as a negative and 
activated by simvastatin as a positive control. 
 
III.2.3. Dual-Luciferase Reporter assay 
 
III.2.3.1. Principle of the Dual-Luciferase Reporter assay system 
 
The Dual-Luciferase Reporter (DLR) assay (Promega) is an advanced co-
reporter technology integrating firefly (Photinus pyralis) and sea pansy 
(Renilla reniformis) luciferase assays. Although both the firefly and Renilla 
luciferases provide the superior assays characteristics of bioluminescent 
reporters, they possess distinct evolutionary origins and, therefore, have 
dissimilar enzyme structures and substrate requirements.  
Firefly luciferase is a monomeric 61 kDa protein that does not require post-
translational processing for enzymatic activity. Thus, it functions as a genetic 
reporter immediately upon translation. Photon emission occurs via oxidation 
of beetle luciferin in a reaction that requires ATP, Mg2+ and O2. 
Renilla luciferase, a monomeric 36 KDa protein, is composed of 3% 
carbohydrate when purified from its natural source, Renilla reniformis. 
However, like firefly luciferase, post-translational modification is not required 
for activity and enzyme may function as a genetic reporter immediately 
following translation. The luminescent reaction catalyzed by Renilla luciferase 
utilizes O2 and coelenterate luciferin (coelenterazine). 
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In the DLR Assay System, the activities of the firefly and Renilla luciferases 
are measured sequentially from a single lysate. Upon completing the 
measurement of firefly luciferase activity (the ‘experimental’ reporter), the 
firefly luminescence is rapidly quenched, with simultaneous activation of the 
Renilla luciferase luminescent reaction (the ‘control’ reporter activity). Thus, 
the DLR Assay System integrates the two assay chemistries to provide rapid 
quantitation of both reporters co-expressed in the lysates of transfected cells. 
The promoter region of a gene regulated by transcription factor of interest 
(SREBP) is cloned into pGL-vector polylinker (Promega) in front of the firefly 
luciferase gene (Figure 5). The enzymatic activity of the luciferase as reporter 
gene in transfected HEK-293 cells is directly proportional to its transcriptional 
activation which in turn is proportional to the transcriptional activity of the 
transcription factor (SREBP) and is normalized with the Renilla luciferase 
internal control constitutively expressed from pRL-CMV (Promega). 
 
 
 
Figure 5. pGL2-Basic Vector (Promega). 
 
Measurement of firefly and Renilla luciferases was performed on a Microlumat 
Plus according to the manuals of the luminometer (LB 96V EG & G Berthold, 
Bad Wildbad, Germany) and of the kit. The firefly luciferase reporter assay 
was initiated by injecting 50 µl of the Luciferase Assay Reagent II (LAR II) to 
the 20 µl lysate into 96-well plate. After a delay time 1 s RLU-measurement 
was integrated during 5 s (with subtraction of background). Upon completion 
of the firefly luciferase assay, the firefly luminescence is quenched and Renilla 
luminescence is simultaneously activated by injecting 50 µl of the Stop & Glo 
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Reagent to the sample well. After delay time of 1 s RLU-measurement was 
integrated during 5 s (without subtraction of back ground). The Stop & Glo 
Reagent quenches the luminescence signal from the firefly reaction by >105-
fold within 1 s. The simultaneous activation of Renilla luciferase is also 
achieved within this period.  
  
III.2.3.2. Setup for the Dual-Luciferase Reporter assay 
 
Monolayers of human embryonic kidney (HEK)293 and hepatoma (Hep)G2 
cells were set up (day 0, 5 × 106 cells/100 mm poly-D-lysine-coated dish) and 
cultured (37°C, 5% CO2) in Dulbecco's Modified Eagle Medium (DMEM) 
(Invitrogen) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin 
(Sigma) and 5% (v/v) fetal bovine serum (FBS) (Invitrogen) for 15 h. 
Transfection was carried out using GenePorter2 Reagent kit (Gene Therapy 
Systems, San Diego, CA, USA) according to the manufacturer's directions. 
Luciferase reporter assays were performed by co-transfection with 8.4 µg 
luciferase reporter gene constructs and 0.2 µg pRL-CMV (Promega), a 
plasmid encoding the Renilla luciferase, as an internal control for transfection 
efficiency into HEK293 cells seeded in 100 mm dishes. The cells were 
incubated for 7 h, trypsin-treated, and transferred to medium A (DMEM 
supplemented with 5% (v/v) FBS, 100 U/ml penicillin, and 100 g/ml 
streptomycin) or medium B (DMEM supplemented with 5% (v/v) calf 
lipoprotein-deficient serum (LPDS) (Sigma), 100 U/ml penicillin, and 100 
g/ml streptomycin). Than the cells were distributed over 96-well plates and 
incubated for 17 h. Each well contained 2x104 viable cells.  
Twenty-four hours after transfection, certain drugs or active compounds were 
added to indicated final concentrations. As a control of the inhibition of the 
SREBP-regulated reporter genes, the cells were incubated with 1 µg/ml 25-
hydroxycholesterol and 10 µg/ml cholesterol (Sigma); as a control of the 
activation of the SREBP-regulated reporter genes, the cells were incubated 
with the dihydroxy-open form of simvastatin at final concentrations of 3x104 or 
4x104 nmol/l. 
Following incubation for 24 h, the media were discarded, the cells were 
washed with 1x PBS, and passive lysis buffer (25 l/well; Promega) was 
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added. The 96-well plates were shaken for 20 min. The luciferase and Renilla 
activities were determined by the Dual-LuciferaseTM Reporter Assay System 
(Promega). Luciferase activities were normalized according to the Renilla 
activities. Luciferase activity was measured with a Microlumat Plus according 
to the manuals of the luminometer (LB 96V EG & G Berthold). 
 
III. 2.4. Isolation of lymphocytes 
 
To 7 ml Lymphodex (Gull Laboratories, Salt Lake City, UT, USA) 7 ml 
heparinized blood was added without mixing the phases. The tubs were 
centrifuged at 3500 x g for 10 min. The upper yellow phase (plasma) was 
discarded and the medium colorless phase (lymphocytes) was transferred to 
a tube containing 30 ml PBS. The tubs were centrifuged at 1000 x g for 10 
min. The supernatant was discarded; the pellet was resuspended in 1 ml 
Trizol reagent (Invitrogen) and used for total RNA extraction. 
 
III.2.5. Extraction of total cellular RNA from human lymphocytes and 
cultured cells 
 
Total cellular RNA was isolated using Trizol reagent (Invitrogen) followed by 
the RNeasy total RNA isolation mini kit (Qiagen) according to the 
manufacturer's instructions. Cells were washed once rapidly with phosphate-
buffered saline, lysed by adding 1.5 ml Trizol reagent to the plates, removed 
from the plates and transferred to Eppendorf tubes. Chloroform (300µl; 
Sigma) was added, the phases were mixed and centrifuged for 10 min at 13 
000 x g. The superior layers were carefully removed and applied onto the 
RNeasy spin column. RNA was recovered in RNase-free water and quantified 
by spectrophotometry at 260 nm. The quality of the RNA was checked by 
examining ribosomal RNA bands after agarose gel electrophoresis and by 
amplifying GAPDH as a control. No RNA degradation due to storage was 
found. 
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III.2.6. Reverse transcription (RT) 
 
cDNA was made by reverse transcribing 5 µg total RNA using the enzyme 
SuperScript II (Invitrogen) and random hexamers primers (Promega) 
according to the manufacturer's directions. DNase treatment was deemed 
unnecessary for quantitative PCR as the amplicons for GAPDH and SREBP-1 
span intron/exon boundaries and genomic DNA contaminants would not 
amplify under the limiting thermocycling conditions used. The total RNA was 
first incubated with 100 ng of random hexamer primers (Promega) and 200 
µM of dNTP (PeqLab, Erlangen, Germany) at 65°C for 7 minutes and then 
reverse-transcribed at 42°C for 1 hour in a reaction mix containing final 
concentration of 1x first strand buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 
mM MgCl2), 100 mM dithiothreitol, 200 units of SuperScript II Reverse 
Transcriptase, and 40 units of ribonuclease inhibitor RNAsin (Promega).  
 
III.2.7. Polymerase chain reaction (PCR) 
 
PCR was performed on a Perkin Elmer 9700 thermocycler with 100-200 ng of 
genomic DNA or 100 ng of cDNA obtained from the reverse transcription of 
total RNA. To the DNA template the following compounds were added: a set 
of primers (0.5 µM), 1.25 units of Taq DNA polymerase (Qiagen), 2.5 µl 10x 
PCR buffer (Qiagen), MgCl2 at a final concentration of 1.5 µM, dNTP 
(PeqLab) at a final concentration of 200 µM and a water to a final volume of 
25 µl. The reaction was incubated for 3 min at 95°C to activate Taq DNA 
polymerase in order to get a hot start PCR. Subsequently 35-39 cycles of 30 s 
denaturation at 94°C, 1 min annealing at a primer specific temperature (55 to 
60°C) and 40 s to 5 min extension at 72°C were performed. After the last 
cycle, the reaction was maintained for 10 min at 72°C for terminal elongation. 
Semi-quantitative multiplex PCR for SREBP-1 and GAPDH cDNAs was done 
in 22-25 cycles in such a way that PCR amplification is still in log-linear 
phase.  
The PCR and RT-PCR products were analyzed by 1-2% agarose gel 
electrophoresis, and band intensities were compared by imaging of ethidium 
bromide (0.5 µg/ml) staining. 
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III.2.8. Generating of stable tetracycline-inducible cell lines  
 
III.2.8.1. Principle of the T-REx System   
 
The T-Rex System is a tetracycline - regulated mammalian expression system 
that uses regulatory elements from the E. coli Tn10-encoded tetracycline (Tet) 
resistance operon (Hillen and Berens, 1994; Hillen et al., 1983). Tetracycline 
regulation in the T-REx System is based on the binding of tetracycline to the 
Tet repressor and derepression of the promoter controlling expression of the 
gene of interest (Yao et al., 1998). The major components of the T-REx 
System include: an inducible expression plasmid, pcDNA4/TO, for expression 
of a gene of interest under the control of the strong human cytomegalovirus 
immediate-early (CMV) promoter with two tetracycline operator 2 (TetO2) sites 
and a regulatory plasmid, pcDNA6/TR, which encodes the Tet repressor 
(TetR) under the control of the human CMV promoter. 
In the T-REx System, expression of our gene of interest is repressed in the 
absence of tetracycline and induced in the presence of tetracycline (Yao et 
al., 1998). Tetracycline-regulated gene expression in the T-REx  System more 
closely resembles the regulation of the native bacterial tet operon (Hillen and 
Berens, 1994) and avoids the potentially toxic effects of viral transactivation 
domains observed in some mammalian cell lines. 
The major component of the T-REx System is the inducible expression 
plasmid pcDNA4/TO. Expression of gene of interest from the inducible 
expression vector is controlled by the strong CMV promoter into which 2 
copies of the tet operator 2 (TetO2) sequence have been inserted in tandem. 
The TetO2 sequences consist of 2 copies of the 19 nucleotide sequence, 5´-
TCCCTATCAGTGATAGAGA-3´ separated by a 2 base pair spacer (Hillen 
and Berens, 1994). Each 19 nucleotide TetO2 sequence serves as the binding 
site for 2 molecules of the Tet repressor. The second major component of the 
T-REx System is the pcDNA6/TR  regulatory vector which expresses high 
levels of the TetR gene (Postle et al., 1984) under the control of the human 
CMV promoter. Both T-REx vectors can be introduced into mammalian host 
cells by standard transfection methods. 
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III.2.8.2. Mechanism of repression 
 
In the absence of tetracycline, the Tet repressor forms a homodimer that 
binds with extremely high affinity to each TetO2 sequence in the promoter of 
the inducible expression vector (Hillen and Berens, 1994). The 2 TetO2 sites 
in the promoter of the inducible expression vector serve as binding sites for 4 
molecules (or 2 homodimers) of the Tet repressor (Figure 6).  
 
 
 
Figure 6. The components of the T-REx System. 
 
Binding of the Tet repressor homodimers to the TetO2 sequences represses 
transcription of gene of interest. Upon addition, tetracycline binds with high 
affinity to each Tet repressor homodimer in a 1:1 stoichiometry and causes a 
conformational change in the repressor that renders it unable to bind to the 
Tet operator. The Tet repressor:tetracycline complex then dissociates from 
the Tet operator and allows induction of transcription from the gene of 
interest.  
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III.2.8.3. Generating T-REx-293 cell lines stably expressed human 
SREBP-1 isoforms 
 
The T-REx-293 cell lines, provided from Invitrogen, stably express the Tet 
repressor from the pcDNA6/TR plasmid and were maintained in medium 
containing antibiotic blasticidin (5 µg/ml). To generate stable tetracycline-
inducible SREBPs cell lines, the coding regions for wild-type SREBP-1c, 
SREBP-1c containing the single-nucleotide polymorphism 3’322C/G and the 
splice variant SREBP-1d were subcloned from the pcDNA3 expression vector 
into pcDNA4/TO inducible expression vector (Invitrogen) using Hind III and 
Xho I restriction sites. The yielding plasmids were designated pcDNA4/TO-
wtSREBP-1c, pcDNA4/TO-SREBP-1c-3’322C/G and pcDNA4/TO-SREBP-1d. 
To obtain stable transfectants, pcDNA4/TO-SREBPs constructs were 
linearized before transfection. Linearizing decreased the likelihood of the 
vector integrating into the genome in a way that disrupts the gene of interest 
or other elements required for mammalian expression. It is important that 
insert does not contain this restriction enzyme site. Suitable restriction 
enzymes for linearization of SREBPs plasmids was Nru I enzyme (New 
England Biolabs). Transfection was performed in dishes of 100 mm diameter 
according to the protocol for transient transfection with GenePorter2 Reagent 
(Gene Therapy Systems). About 24 hours post transfection, the medium was 
exchange to medium supplemented with 200 µg/ml of Zeocin. The amount of 
Zeocin required to kill cells not expressing the construct was titrated for T-
REx-293 cell lines. The medium was exchanged for every 3-4 days. This is 
the time needed for the Zeocin to act on the nontransfected cells, which then 
detach and washed away during the medium exchange. Once all cells have 
died in the dish of the negative control (nontransfected), it can be proceed 
with the cloning.  
To pick colonies 24-well dishes with 1 ml media containing 200 µg/ml Zeocin 
in each well were prepared. The dish was rinse with PBS and warm PBS 
containing 5% trypsin was added. Colonies were picked on an inverted light 
microscope using an Eppendorf pipette with sterile tip. The tip was lowered to 
the surface of colony of interest and scraped and sucked gently until the cells 
were pulled up into the tip. The colony was then transferred to a well in the 
Materials and Methods 
40 
24-well plate. In a one or two days, when the wells were confluent, cells were 
trypsinized with 100 µl of trypsin-EDTA solution and splited into one well of a 
6-well plate. At the level of 6-well plates, it was possible to make a first 
cryotube of each selected clone. 
 
III.2.8.4. Screening of clones for SREBP-1 expression in T-REx-293 cells 
 
The clones were screened for SREBP-1 expression by plating on 60-mm 
dishes at a density of 1 million cells/100mm dish and cultured in medium A 
(DMEM supplemented with 5% (v/v) FBS, 100 units/ml penicillin, and 100 
g/ml streptomycin) for 16 h in the presence or absence of 1 µg/ml 
tetracycline. After the total RNA isolation (Qiagen), cDNA was prepared 
(Invitrogen) and analyzed by semi-quantitative RT-PCR for induction of 
SREBP-1c, SREBP-1c-3’322C/G and SREBP-1d in the presence or absence 
of tetracycline as described above. The cell line stabily transfected with the 
pcDNA4/TO expression vector was used as a control for tetracycline induction 
of endogenous SREBP-1. 
 
III.2.9.Quantitative PCR with TaqMan assay 
 
III.2.9.1. Principle of TaqMan assay 
 
The PCR reaction exploits the 5´ nuclease activity of AmpliTaq Gold DNA 
Polymerase to cleave a TaqMan probe during PCR. The TaqMan probe 
contains a reporter dye at the 5´ end of the probe and a quencher dye at the 
3´ end of the probe. During the reaction, cleavage of the probe separates the 
reporter dye and the quencher dye, which results in increased fluorescence of 
the reporter. Accumulation of PCR products is detected directly by monitoring 
the increase in fluorescence of the reporter dye. The figure 7 shows the 
polymerization-associated 5´ to 3´ nuclease activity of AmpliTaq Gold enzyme 
during PCR. When the probe is intact, the proximity of the reporter dye to the 
quencher dye results in suppression of the reporter fluorescence primarily by 
Förster-type energy transfer (Förster, 1948; Lakowicz, 1983). During PCR, if 
the target of interest is present, the probe specifically anneals between the 
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forward and reverse primer sites. The 5´ to 3´ nucleolytic activity of the 
AmpliTaq Gold enzyme cleaves the probe between the reporter and the 
quencher only if the probe hybridizes to the target. The probe fragments are 
then displaced from the target, and polymerization of the strand continues.  
 
 
 
Figure 7. Schematic representation of the TaqMan assay during one extension 
phase of PCR.  
 
The 3´ end of the probe is blocked to prevent extension of the probe during 
PCR. This process occurs in every cycle and does not interfere with the 
exponential accumulation of product. The increase in fluorescence signal is 
detected only if the target sequence is complementary to the probe and is 
amplified during PCR. Because of these requirements, non-specific 
amplification is not detected. 
 
III.2.9.2. Setup for TaqMan assay 
 
For TaqMan analysis of mRNA abundance, stably transfected T-Rex-293 cells 
were plated on 60-mm dishes at a density of 1 million cells/dish and cultured 
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in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine 
serum for 16 h in the presence of 1 µg/ml tetracycline. Transcription was 
inhibited by the addition of actinomycin D (Sigma). Actinomycin D (5 µg/ml) 
was added to the growth medium, and the cells were incubated for the 
indicated time. Total cellular RNA from stably transfected cells was isolated 
using Trizol reagent (Invitrogen) followed by an RNeasy total RNA isolation 
mini-prep system (Qiagen). cDNA was used as a template for the real-time 
PCR analysis based on the 5'-nuclease assay with the ABI PRISM 7000 
Sequence Detection System (Applied Biosystems, PE Europe B.V., Rotkreuz, 
Switzerland). PCR primers and TaqMan probe were designed by using 
Primer-Express software (Applied Biosystems). The probe was labeled with 
the fluorescent dyes 6-carboxyfluorescein (6FAM) on the 5' end and minor 
groove binder/non-fluorescent quencher (MGB) on the 3' end. Expression of 
human SREBP-1c gene was analyzed using forward primer: 3’- CGG AGC 
CAT GGA TTG CA-5’, reverse primer: 3’- AGC ATA GGG TGG GTC AAA 
TAG G-5’ and the probe: 6FAM-TTT CGA AGA CAT GCT TCA-MGB. The 
probe was placed across the exon 1c/exon 2 boundary amplifying only that 
transcript which corresponded to human SREBP-1c. Glyceraldehyde 
phosphate dehydrogenase (GAPDH) was amplified from all samples on each 
plate as a housekeeping gene to normalize expression between different 
samples and to monitor assay reproducibility. GAPDH mRNA was quantified 
by RT-PCR using primers and probes purchased from Applied Biosystems 
Assays-on-Demand #Hs99999905_m1. cDNA corresponding to 15 ng of 
reverse transcribed total RNA was amplified in a 25 µl volume reaction using 
TaqMan universal PCR Master Mix (Applied Biosystems) in triplicate assays 
for both SREBP-1c targets and the endogenous control GAPDH. Primers for 
SREBP-1c gene (Applied Biosystems) were used at a concentration of 300 
nM each, FAM/MGB fluorophore/non-fluorescent quencher reporter probe 
(Applied Biosystems) at a concentration of 200 nM. Thermocycling conditions 
were as for standard TaqMan protocol (Applied Biosystems), 10 min 
denaturation at 95°C followed by 40 cycles of 95°C for 15 s, 60°C for 60 s. 
The primers and probe were validated for amplification efficiency by running 
the reaction at different dilutions of template and subtracting the results 
obtained for the control GAPDH from those of the target, this established that 
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the amplification efficiency was the same for all primer pairs. Relative 
quantification of all targets was calculated by the comparative cycle threshold 
(Ct) method outlined in user bulletin No. 2 provided by Applied Biosystems. 
The Ct is the cycle number at which the fluorescence of the sample crosses a 
given threshold. This threshold is set within the linear log phase of each 
reaction, i.e. where amplification of the product is still exponential and 
therefore a direct correlation can be made with the relative amounts of starting 
template in each reaction. The expression levels of the wild-type SREBP-1c 
was arbitrarily taken as the ‘calibrator' for all calculations. A non-template 
control was included for each target analyzed. 
 
III.2.10.Statistical methods 
 
RepGene, a spreadsheet template for the management of reporter gene 
assays was used for planning and evaluation of the experiments (Muller et al., 
2001). The significance level of differences of means from normally distributed 
values was determined by one way and two way Analysis of Variance 
(ANOVA) using StatView 4.5 (Abacus Concepts Inc., Berkeley, CA, USA). 
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III. Results 
 
III.1. The role of SREBP-1c in drug induced hyperlipidemia 
 
III.1.1. The effects of HIV-protease inhibitor indinavir on SREBP-1c 
 
III.1.1.1. Indinavir inhibits SREBP-1c-dependent lipoprotein lipase and 
fatty acid synthase gene activations 
 
As it has been outlined before, SREBP-1c is primarily involved in the 
regulation of the fatty acids, triglyceride and glucose metabolism, whereas 
SREBP-2 is mainly involved in the regulation of cholesterol. Therefore we 
constructed reporter genes, which allowed us to differentiate between the 
activation of SREBP-1c and SREBP-2, respectively.  
To measure the activation of SREBP-1c, we transfected human embryonic 
kidney (HEK) 293 cells with a fatty acid synthase (FAS) and a lipoprotein 
lipase (LPL) reporter genes. To measure the activation of SREBP-2, HEK 293 
cells were transfected with low-density lipoprotein receptor (LDLR) reporter 
gene. Twenty-four hours after transfection, indinavir was added at final 
concentrations of 0, 10-3, 10-2,10-1, 1, 101, 5x101, 102, 2x102, 7.5x102, 103, 
2x103, 5x103, 2x104, and 105 nmol/l. As a control of the inhibition of the 
SREBP-regulated reporter genes, the cells were incubated with 25-
hydroxycholesterol (1 µg/ml) and cholesterol (10 µg/ml); as a control of the 
activation of the SREBP-regulated reporter genes, the cells were incubated 
with the dihydroxy-open form of simvastatin at final concentrations of 3x104 or 
4x104 nmol/l. 
Following incubation for 24 h, the luciferase and Renilla activities were 
determined by the Dual-LuciferaseTM Reporter Assay System as described in 
Materials and Methods. Luciferase activities were normalized according to the 
Renilla activities.  
It has been found that indinavir inhibited the LPL and FAS reporter gene 
activities, measured as normalized relative light units, in a dose-dependent 
fashion (Figure 8 A, B).  
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Figure 8. The effect of indinavir on the sterol-regulatory element-binding protein-1c 
(SREBP-1c)-dependent gene expression. (A) Effect on expression of the gene 
encoding the lipoprotein lipase (LPS). (B) Effect on expression of the gene encoding 
the fatty acid synthase (FAS). (C) Effect on expression of the gene encoding the low-
density lipoprotein receptor (LDLR). Three independent experiments (A-C), each 
performed in duplicate, showing changes in the Renilla-normalized luciferase 
activities (±SEM) of the LPL, FAS, and LDLR reporter gene constructs. Changes are 
given as percentage from baseline activation of the SREBP-1c (LPL and FAS) and 
the SREBP-2 (LDLR) pathways. Sterols decrease (inhibition control, first bar in each 
panel) and sterol depletion increases (stimulation control, second bar in each panel) 
the endogenous SREBP-1c and SREBP-2 pathways, reflected by the respective 
reporter gene activities. The cells maintained their triglyceride and cholesterol 
homeostasis by a basal SREBP-1c gene activity (baseline, third bar). Indinavir 
inhibited LPL and FAS gene activities in a dose-dependent fashion but did not inhibit 
the LDLR gene activity.  
 
ANOVA confirmed the significance of the interaction between the different 
indinavir concentrations and the inhibition of the LPL gene activity (P = 
0.0158) as well as the interaction between the different indinavir 
concentrations and the inhibition of the FAS gene activity (P = 0.0358). 
Indinavir did not inhibit the LDLR reporter gene activity significantly. 
 
In the LPL reporter gene experiments, inhibition of the gene activity was 
detectable starting from an indinavir concentration of 1 nmol/l. At a 
concentration of 103 nmol/l, indinavir inhibited the LPL gene activity from 
baseline by 12.4% but did not reach a plateau at this concentration. At the 
highest concentration tested (105 nmol/l) indinavir inhibited the LPL gene 
activity from baseline by 57.1% (difference baseline versus highest 
concentration: P = 0.041) (Figure 8A). 
 
In the FAS reporter gene experiments, inhibition of the gene activity was 
detectable starting from an indinavir concentration of 10–2 nmol/l. At a 
concentration of 103 nmol/l, indinavir inhibited the FAS gene activity from 
baseline by 30.3%. The effect reached a plateau at this concentration (Figure 
8B). 
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III.1.1.2. Reversibility of indinavir effects 
 
To determine whether indinavir-induced inhibition of the activation of the 
SREBP-dependent genes was reversible or not, two sets of HEK293 cells 
were cotransfected with pGL2-FAS luciferase reporter gene constructs and 
with Renilla luciferase. These experiments were identical to those described 
above except that two sets of cells were used instead of one. Both sets of 
cells were first incubated with indinavir for 24 h at the concentrations specified 
above. Thereafter, indinavir was completely washed out with 1 × PBS. The 
first set of cells was incubated for another 24 h with fresh medium without 
indinavir. The second set of cells was incubated for another 24 h with fresh 
medium again containing indinavir at various concentrations. After incubation, 
the cells were harvested to determine the activation of the SREBP-dependent 
genes as described in Materials and Methods. 
After a second incubation period, no statistically significant differences 
regarding the indinavir-induced inhibition of the SREBP-dependent genes 
were detectable between the two series. It was, therefore, concluded that 
indinavir-induced effects were not reversible. 
 
III.1.1.3. Antagonization of indinavir effects by simvastatin 
 
Toxicity of indinavir causing a decrease in the viability of the cells with 
increasing concentrations of indinavir was first excluded on the morphological 
level. Cell toxicity was not detected microscopically, even at high indinavir 
concentration (>103 nmol/l). Cell toxicity as an explanation for the decrease of 
the LPL and FAS gene activities attributed to indinavir was further excluded 
by incubating the cells with the active dihydroxy-open form of simvastatin, a 
strong activator of the SREBP pathways. The net effects of the combination of 
simvastatin (constant final concentration of 3 × 104 nmol/l) and indinavir (final 
concentrations of 10, 5 × 101, 102, 2 × 102 nmol/l) were determined following 
24 h of incubation with the respective combinations.  
When simvastatin was combined with various concentrations of indinavir, the 
cells were still able to upregulate the SREBP-1c-dependent genes, as shown 
for FAS (Figure 9): increasing concentrations of indinavir (0, 10, 5 × 101, 102, 
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and 2 × 102 nmol/l) decreased the rate of the gene activation induced by a 
constant simvastatin concentration (3 × 104 nmol/l) again in a dose-dependent 
fashion. At an indinavir concentration of 2 × 102 nmol/l combined with a 
simvastatin concentration of 3 × 104 nmol/l, the FAS gene activity decreased 
by 36.4 % compared with the activation achieved with simvastatin alone. 
However, the combination of 3 × 104 nmol/l simvastatin with 2 × 102 nmol/l 
indinavir still resulted in a net activation of the gene, demonstrating that the 
cells maintained their ability to upregulate their SREBP-1c-dependent genes 
despite the presence of indinavir (Figure 9). 
 
 
 
Figure 9. Antagonization of the indinavir-induced inhibition of sterol-regulatory 
element-binding protein (SREBP)-dependent genes by simvastatin. Experiments 
performed in duplicates showing changes in Renilla-normalized luciferase activities 
(±SEM) of the fatty acid synthase (FAS) reporter gene constructs. Changes are given 
as percentage from the respective baselines. If the activation by simvastatin is 
defined as baseline, indinavir inhibits the simvastatin-induced activation of the FAS 
gene activity in a dose-dependent fashion by 12.1% (indinavir at a final concentration 
of 10 nmol/l), 12.7% (5 × 101 nmol/l), 13.5% (102 nmol/l), and 36.4 % (2 x 102 nmol/l). 
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If the FAS gene activity without simvastatin is defined as baseline, simvastatin 
entirely antagonizes the indinavir-induced inhibition of the FAS gene activity resulting 
in a net activation of the FAS gene of 87.4% (indinavir at a final concentration of 10 
nmol/l), 86.9% (5 x 101 nmol/l), 86.1% (102 nmol/l), and 63.2% (2 × 102 nmol/l).  
 
The effects of indinavir on the LPL and FAS reporter genes were similarly 
detectable when liver cells (HepG2 cells) instead of HEK293 cells were 
transfected (data not shown). The effects of indinavir on the LPL and FAS 
reporter genes were also detectable when the cells were incubated in FCS or 
LPDS media. Indinavir, sterols or simvastatin did not influence the activity of 
the empty vectors (pGL, pRL) (data not shown). 
 
III.1.2. The role of single-nucleotide polymorphism in the SREBP-1c gene 
in protease inhibitor-induced hyperlipoproteinemia 
 
III.1.2.1. The human SREBP-1c single-nucleotide polymorphism 
3’322C/G in exon 18c is not associated with alternative splicing 
 
To investigate the molecular basis of SNP-associated differences, we first 
excluded the possibility that SREBP-1c-3’322G causes alternative splicing. 
Various human cDNA libraries and lymphocytes from several patients were 
screened for alternative transcripts by reverse transcriptase polymerase chain 
reaction using primers homologous to exon 17 and 3’-untranslated region of 
SREBP-1c. We did not find an association between the new discovered 
alternative splicing of SREBP-1 at the 3’ end of mRNA and the single-
nucleotide polymorphism 3’322C/G in exon 18c. The splice variants were 
detected in different quantities independently from 3’322C/G genotype 
carriers. This finding demonstrated that the 3’322C/G mutation is not 
associated with new discovered alternative slicing. 
 
III.1.2.2. Putative differences of SREBP-1c mRNA secondary structures 
 
To investigate whether the 3’322C/G SNP might cause functional differences 
on the mRNA level, we compared the secondary structures of the wild-type 
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and mutated mRNA molecules of exon 18c of the SREBP-1c gene, predicted 
by the MFOLD program, version 3.0 (Mathews et al., 1999). This computer-
based analysis discovered the conformational changes of SREBP-1c-
3‘322C/G at the mRNA level. Figure 10 demonstrate the proposed differences 
in the predicted mRNA secondary structure.  
 
 
 
Figure 10. RNA secondary structure prediction using MFOLD 3.0 (Mathews et al., 
1999). 
 
As shown in Figure 10, both SREBP-1c mRNAs have different free energy. 
Wild-type mRNA (C isoform, genotype 11) of SREBP-1c has extended single-
nucleotide stem loop. Whereas mutated mRNA (G isoform, genotype 22) of 
SREBP-1c has an additional nucleotide duplex which increase the stability of 
this isoform. This finding is especially important because we suppose that the 
mRNA stability of the SREBP-1c gene seems to be crucial for its regulation in 
highly active antiretroviral treatment. 
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III.1.2.3. Establishment of the stable T-REx-293 cell lines permitting 
inducible expression of wild-type SREBP-1c and the SREBP-1c 
containing the single-nucleotide polymorphism 3’322C/G 
 
An expression plasmid for human wild-type SREBP-1c was constructed by 
cloning full-length coding sequences and the entire 3' untranslated region (3' 
UTR) including a polyadenylation signal (AATAAA) of SREBP-1c from HeLa 
cDNA library into the pcDNA3 expression vector. To obtain a fragment 
containing the sequence variant in exon 18c (3’322C/G), in vitro mutagenesis 
was applied to part of the exon 18c of the SREBP-1c gene. For the mRNA 
stability experiments two different full-length cDNAs, the wild-type SREBP-1c 
and the SREBP-1c containing the single-nucleotide polymorphism 3’322C/G 
(SREBP-1c-3’322C/G), were compared. The T-REx inducible system to 
achieve tightly controlled and conditional expression of the SREBP-1c 
isoforms in 293 cells was employed. For that both full-length cDNA inserts 
(SREBP-1c-3’322C and SREBP-1c-3’322G) were cloned into the multiple 
cloning site of the inducible tetracycline-regulated expression (T-REx) vector 
pcDNA4/TO (Invitrogen).  
T-REx-293 cells, which stably express the tetracycline (Tet) repressor, were 
transfected with expression vector pcDNA4/TO, carrying the wild-type 
SREBP-1c or SREBP-1c-3’322C/G. Two-round stable transfection 
experiments were performed, and several zeocin-resistant clones selected. 
The clones were screened for the wild-type SREBP-1c and SREBP-1c-
3’322C/G expression by culturing the cells in medium in the presence or 
absence of tetracycline (1 µg/ml). RNA and cDNA were prepared and 
analyzed by semi-quantitative RT-PCR for induction of SREBP-1c and 
SREBP-1c-3’322C/G with tetracycline as described in Materials and Methods. 
The cell line stably transfected with pcDNA4/TO vector was used as a control 
for tetracycline induction of endogenous SREBP-1c. After screening by semi-
quantitative RT-PCR for induction of SREBPs, we established zeocin-
resistant clones which positively express the transgenes. These clones, 
termed wt-SREBP-1c and SREBP-1c-3’322C/G, which actually represented 
almost undetectable background expression under non-induced conditions, 
show remarkable expression of different SREBPs mRNA after tetracycline 
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induction (Figure 11). These stable cell line (wt-SREBP-1c and SREBP-1c-
3’322C/G) were used as a tool to study the influence of SREBP-1c SNP 
3’322C/G on mRNA stability and explain disorders in lipid metabolism in HIV-
1-infected patients after PIs treatment. 
 
 
 
Figure 11. The tetracycline induce stably transfected wild-type SREBP-1c and the 
SREBP-1c-3’322C/G in T-REx-293 cells. T-REx-293 cells stably transfected with 
indicated expression constructs (wild-type SREBP-1c and SREBP-1c-3’322C/G) 
were treated for 16 hours with tetracycline (1 µg/ml). The cell line stably transfected 
with pcDNA4/TO vector was used as a control for tetracycline induction of 
endogenous SREBP-1c. Total RNA (5 µg) was used to prepare cDNA by reverse 
transcription with random hexamers primers followed by the semi-quantitative RT-
PCR using primers homologous to exon 17 and 3’-untranslated region of SREBP-1c 
(F ex17 and R 3’UTR primers, respectively) (A) and the internal control GAPDH (B) 
as indicated. PCR products were resolved by electrophoresis on a 2% agarose gel 
containing ethidium bromide. M, DNA molecular weight marker V (Roche Diagnostics 
AG, Rotkreuz, Switzerland). C, control (no template). 
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III.1.2.4. Characterization of wild-type SREBP-1c and the SREBP-1c-
3’322C/G stable transformants by transient transfection of luciferase 
reporter constructs 
 
Two luciferase reporter constructs containing the promoter region of fatty acid 
synthase gene (pGL2-FAS) and lipoprotein lipase gene (pGL2-LPL) were 
used for characterization of SREBP-1 stable transformants in T-REx-293 
cells. Each luciferase reporter construct was transfected into T-REx-293 cell 
lines stably expressed either with wild-type SREBP-1c or the SREBP-1c 
containing the SNP 3’322C/G (SREBP-1c-3’322C/G). After transfection, the 
cells were incubated with tetracycline (1 µg/ml) for induction of wild-type 
SREBP-1c and SREBP-1c-3’322C/G isoforms. The cell line, stably 
transfected with the pcDNA4/TO vector only, was used as a control for 
tetracycline induction of endogenous SREBP-1c. After induction of SREBPs, 
cells were treated with 25-hydroxycholesterol and cholesterol as a control of 
the inhibition of the SREBP-regulated reporter genes; and with the dihydroxy-
open form of simvastatin as a control of the activation of the SREBP-regulated 
reporter genes.  
Figure 12 compares the ability of wild-type SREBP-1c and the SREBP-1c-
3’322C/G to induce transcription of the FAS and LPL luciferase reporter 
genes. Both, wild-type SREBP-1c and SREBP-1c-3’322C/G, transformants 
exhibit relatively strong transactivation of the transiently transfected reporters 
constructs in comparison with a control cell line, stably transfected with the 
pcDNA4/TO expression vector. As shown in Figure 12, the SREBP-1c-
3’322C/G produced a transcriptional response that was significantly larger 
than the wild-type SREBP-1c when simvastatin, a SREBPs agonist, was 
added to the culture medium. The SREBP-1c-3’322C/G isoform activated the 
FAS and LPL reporter genes greater (1.6-fold, P = 0.007 and 2.7-fold, P = 
0.0007, respectively) than wild-type SREBP-1c isoform. 
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Figure 12. Characterization of SREBP-1 stable transformants of T-REx-293 cells by 
transient transfection of luciferase reporter constructs. The luciferase reporter 
constructs containing the promoter region of fatty acid synthase (pGL2-FAS) and 
lipoprotein lipase (pGL2-LPL) were co-transfected with the pRL-CMV vector 
containing Renilla luciferase into T-REx cell lines, stably expressing either wild-type 
SREBP-1c or the SREBP-1c containing SNP 3’322C/G (SREBP-1c-3’322C/G). The 
cell line, stably transfected with the pcDNA4/TO vector, was used as a control for 
tetracycline induction of endogenous SREBP-1c. Cells were than treated with 1 
µg/ml 25-hydroxycholesterol and 10 µg/ml cholesterol (Sigma) as a control of the 
inhibition of the SREBP-regulated reporter genes; and with the dihydroxy-open form 
of simvastatin at final concentrations of 1x104, 2x104 and 3x104 nmol/l as a control of 
the activation of the SREBP-regulated reporter genes. For all transfections, activation 
of luciferase was corrected for transfection efficiency with Renilla luciferase activity 
levels, and all data are represented accordingly as relative light units. A. Luciferase 
activity is expressed as the -fold increase relative to untreated (without simvastatin) 
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T-REx cells stably transfected with the pcDNA4/TO vector. B. Comparison of 
maximum activation of FAS and LPL reporter genes by simvastatin (30 µM) in T-REx 
cells stably expressing either wild-type SREBP-1c (grey) or SREBP-1c-3’322C/G 
(black). Luciferase activity of control T-REx cell line was subtracted to luciferase 
activity of cell lines stably transfected with wild-type SREBP-1c and SREBP-1c-
3’322C/G. The error bars indicate S.D. from the mean. *, P = 0.007 (comparison 
between wild-type SREBP-1c and SREBP-1c-3’322C/G for FAS gene); P = 0.0007 
(comparison between wild-type SREBP-1c and SREBP-1c-3’322C/G for LPL). 
 
III.1.2.6. The influence of the SNP 3’322C/G in the SREBP-1c gene on 
mRNA stability 
 
For analysis of mRNA abundance, T-REx-293 cell lines, stably expressing 
either wild-type SREBP-1c or the SREBP-1c containing SNP 3’322C/G 
(SREBP-1c-3’322C/G) were cultured in the presence of tetracycline for the 
induction of these isoforms. Transcription was then inhibited by the addition of 
actinomycin D. Actinomycin D was added to the growth medium (5 µg/ml), 
and the cells were incubated for the indicated time (Figure 13).  
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Figure 13. The influence of the SNP 3’322C/G in the SREBP-1c gene on mRNA 
stability. T-REx-293 cells stably expressing wild-type SREBP-1c and the SREBP-1c-
3’322C/G, were treated for 16 hours with tetracycline (1 µg/ml). Actinomycin D than 
was added to 5 µg/ml, and total cellular RNA was harvested after an additional 1, 2, 
4, 6 or 8 hours. SREBP-1c mRNA levels were evaluated with a real time quantitative 
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polymerase chain reaction method as described in Materials and Methods. The error 
bars indicate S.D. from the mean. The graph depicts the % mRNA remaining after 8 
h of actinomycin D. 
 
Total cellular RNA from stably transfected cells was isolated. cDNA was used 
as a template for the quantitative polymerase chain reaction analysis based 
on the 5'-nuclease assay with the ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems). Figure 13 demonstrates that mRNA of the 
SREBP-1c with 3’322C/G polymorphism is more stable than wild-type 
SREBP-1c mRNA (P = 0.02). SREBP-1c-3’322C/G mRNA has a half-life of 
about 6 hours, whereas wild-type SREBP-1c has a half-life of about 3.5 hours. 
These data suggest that sequence differences in the coding 3’-end of the 
SREBP-1c gene (3’322C/G SNP) affects the secondary structure of the 
SREBP-1c mRNA and influence its degradation rate. 
 
III.2. Alternative splicing of human SREBP-1 
 
III.2.1. Identification and characterization of new splice variants of 
human SREBP-1 
 
In the process of cloning of the SREBP-1c gene for further studies we 
observed a number of different mRNA transcripts indicating possible 
alternative splicing of this gene in humans at the 3’ end of pre-mRNA. We 
analyzed these transcripts using reverse transcriptase polymerase chain 
reaction (RT-PCR) experiments in lymphocytes from several individuals. To 
verify the identity of the PCR products, the bands were excised and subjected 
to DNA sequencing. RT-PCR was conducted using SREBP-1c-specific 
primers that span exon 17 and 3’-untranslated region. First, we identified new 
splice variants in human liver and HeLa cells cDNA libraries. Sequencing of 
these transcripts revealed that they contain various combinations of the a and 
c exons at the 3’ end. For example, liver cDNA mRNAs contain only SREBP-1 
transcript with exons 17, 18a and 18c. It is interesting, that this library does 
not contain wild-type SREBP-1c transcripts. In contrast, HeLa cells cDNA 
library contains wild-type SREBP-1c (with exons 17, 18c and 19c) and 
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another splice variant with exons 17, 18a, 18c and 19c. Second, we analyzed 
the splice variants that are common in human lymphocytes. Total RNA was 
isolated from lymphocytes of various (n=95) individuals, cDNA was prepared 
and subjected to RT-PCR. During this process a third splice variant was 
detected and identified by sequence analysis. This new splice variant 
contained exons 17 and 18c, but exon 19c and a part of the 3’-untranslated 
region were spliced out.  
 
We tentatively designated the human SREBP-1 splice variant containing 
exons 17, 18a and 18c as SREBP-1d. Splice variant containing exons 17, 
18a, 18c and 19c as SREBP-1e, and splice variant containing exons 17 and 
18c as SREBP-1f (Figure 14).  
 
 
 
Figure 14. Splice variants of human SREBP-1 at the 3’ end. 
 
Interestingly, the lymphocytes of the numerous individuals investigated had in 
the most cases (62%) all splice variants at different expression levels (Table 
1). About 13% of them expressed all splice variants except the SREBP-1d 
isoform. Furthermore, the 8% lymphocytes expressed all splice variants 
without wild-type SREBP-1c isoform. The 6% and 5% lymphocytes expressed 
only SREBP-1d and SREBP-1c isoforms or SREBP-1d and SREBP-1f 
isoforms, respectively. The frequency of other combinations of the SREBP-1 
splice variants were more less (1%). 
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SREBP-1e 
 
 
 
SREBP-1d 
 
 
 
SREBP-1c 
 
 
 
SREBP-1c 
 
 SREBP-1 
isoforms in 
lymphocytes, 
% 
+ + + + 62 
 + + + 13 
+ +  + 8 
 +  + 6 
 + +  5 
+  +  1 
 +   1 
+  + + 1 
+ + +  1 
+ +   1 
 
Table 1. The frequency (%) of the SREBP-1 splice variants in human lymphocytes of 
numerous (n=95) individuals. Total RNA (5 µg) from lymphocytes were used to 
prepare cDNA by reverse transcription with random hexamers primers. PCR 
amplification was carried out using primers specific for SREBP-1c exon 17 and 
3’UTR (F ex17 and R 3’UTR primers, respectively). PCR products were analyzed by 
electrophoresis on a 2% agarose gel, and band intensities were compared by 
imaging of ethidium bromide staining. A plus sign denotes presence of certain splice 
variant. 
 
The results of the RT-PCR of the cDNA obtained from lymphocytes of some 
of the individuals (n=4) are illustrated in Figure 15. As a control to compare 
and identify the new splice variants we used liver and HeLa cDNA libraries. In 
agreement with the results described above the individuals had a 
considerable variety of splice variants in different quantities. 
 
 
 
Figure 15. Identification of new splice variants of human SREBP-1 in lymphocytes 
mRNA. Total RNA (5 µg) from lymphocytes were used to prepare cDNA by reverse 
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transcription using random hexamers primers followed by RT-PCR using primers 
homologous to exon 17 and 3’-untranslated region of SREBP-1c (F ex17 primer and 
R 3’UTR primer, respectively). PCR products were resolved by electrophoresis on a 
2% agarose gel containing ethidium bromide. Lymphocytes cDNA of some (n=4) 
patients (lanes 1-4), liver cDNA library (lane 5), HeLa cDNA library (lane 6). SREBP-
1e splice variant containing exons: 17, 18a, 18c and 19c (392 bp); SREBP-1d splice 
variant containing exons: 17, 18a and 18c (338 bp); SREBP-1c splice variant (wild-
type) containing exons: 17, 18c and 19c (280 bp); SREBP-1f splice variant containing 
exons: 17, 18c and 20f (226 bp). M, DNA molecular weight marker V (Roche 
Diagnostics). 
 
Comparison of cDNA sequence of each transcript with the human SREBP-1a 
(NM004176) and SREBP-1c (AH004383) sequence from database revealed 
that exon 18a of human SREBP-1a gene terminates with an incomplete 
codon and exon 18c begins with a complete codon. This leads to a 
resumption of an out-of-frame code and two premature termination codons (6 
amino acids after the splice site) resulting in a predicted truncated protein of 
SREBP-1d.  
The splice variant SREBP-1e is very similar to variant SREBP-1d except that 
after exons 18a and 18c follows exon 19c. In a similar way after exon 18a 
comes the frame shift and consequently a premature termination of the coding 
sequence.  
In splice variant SREBP-1f exon 19c with the termination codon and a part of 
3’ untranslated region is spliced out. The remaining part of the 3’ untranslated 
region sequences has a possible criptic site for alternative splicing. Like all of 
the introns it has AG nucleotides at their 3’ splice acceptor sites (aagGAG). 
As a result of this splicing event the new exon termed 20f (51 amino acids 
after the splice site followed by the termination codon) is created (Figure 14). 
 
III.2.2. Different ways of expression the SREBP-1 isoforms 
 
To further investigate the presence of alternatively spliced SREBP-1 mRNA in 
human normal and tumor tissues, multiple-tissue cDNA panels (Clontech 
Laboratories, Palo Alto, CA, USA) were subjected to PCR analysis using a 
Results 
60 
pair of SREBP-1c-specific primers. A pair of GAPDH-specific primers served 
as internal control. This analysis detected alternatively spliced SREBP-1e 
transcript in all normal tissues and tumor-derived cells at different detectable 
levels (Figure 16). 
 
 
 
Figure 16. The mRNA level of SREBP-1 splice variants in human normal and tumor 
tissues. PCR amplification was carried out on panels of cDNAs from human normal 
tissues (A and B) and tumor tissues (C) using the SREBP-1c-specific primers 
spanning the exon 17 and 3’-untranslated region (F ex17 primer and R 3’UTR primer, 
respectively). The upper panels in each set show 392 bp, 338 bp, 280 bp and 226 bp 
DNA fragments amplified for SREBP-1e (39 cycles), SREBP-1d (39 cycles), SREBP-
1c (39 cycles) and SREBP-1f (39 cycles), respectively, in a agarose gel 
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electrophoresis. The lower panels in each set exhibit 261 bp cDNA fragments 
amplified for human glyceraldehydes phosphate dehydrogenase (GAPDH, 25 
cycles). C, control (no template). M, DNA molecular weight marker V (Roche 
Diagnostics). A, lane 1, heart; lane 2, brain; lane 3, placenta; lane 4, lung; lane 5, 
liver; lane 6, skeletal muscle; lane 7, kidney; lane 8, pancreas. B, lane 1,spleen; lane 
2, thymus; lane 3, prostate; lane 4, testis; lane 5, ovary; lane 6, small intestine; lane 
7, colon; lane 8, peripheral blood leukocyte. C, lane 1, breast carcinoma (GI-101); 
lane 2, lung carcinoma (LX-1); lane 3, colon adenocarcinoma (CX-1); lane 4, lung 
carcinoma (GI-117); lane 5, prostatic adenocarcinoma PC3); lane 6, colon 
adenocarcinoma (GI-112); lane 7, ovarian carcinoma (GI-102); lane 8, pancreatic 
adenocarcinoma (GI-103). 
 
cDNA Panel I 
 
 
1 
 heart 
2  
brain 
3  
placenta 
4  
lung 
5  
liver 
6  
skeletal 
muscle 
7 
 kidney 
8 
 pancreas 
SREBP- 
1e ± ± + ± + + + + 
SREBP-
1d   ± ± +  ± ± 
SREBP-
1c   ±  ±    
SREBP-1f 
        
 
cDNA Panel II 
 
 
1  
spleen 
2  
thymus 
3  
prostate 
4  
testis 
5  
ovary 
6  
small 
intestine 
7  
colon 
8  
perif. blood 
leukocytes  
SREBP-
1e + + + + + + + + 
SREBP-
1d + + + + + + ± + 
SREBP-
1c ± ±      ± 
SREBP-1f 
       ± 
 
Tumor cDNA Panel  
 
 
1 
 breast 
carcin. 
GI-101 
 
2  
lung 
carcin. 
LX-1 
3  
colon 
adenocarc. 
CX-1 
4  
lung 
carcin. 
GI-117 
5  
prostatic 
adenocarcin. 
PC3 
6  
colon 
adenocarcin. 
GI-112 
7 
ovarian 
carcin. 
GI-102 
8 
pancreatic 
adenocarin. 
GI-103 
SREBP- 
1e ± + + + ± + + ± 
SREBP-
1d ± + ± +  ± ± ± 
SREBP-
1c ± + ± ±  ± ±  
SREBP-
1f         
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Table 2. The mRNA level of SREBP-1 splice variants in human normal and tumor 
tissues. PCR products were analyzed by electrophoresis on a 2% agarose gel, and 
band intensities were compared by imaging of ethidium bromide staining. A plus sign 
denotes high expression level of certain splice variant. A plus/minus sign denotes low 
expression level of certain splice variant. 
 
The highest expression level was detected in liver, placenta, pancreas, testis, 
thymus and prostate tissues, and in lung carcinoma (LX-1 and GI-117), colon 
adenocarcinoma (CX-1 and GI-112) and ovarian carcinoma (GI-102) in the 
case of the tumor-derived cells (Table 2). The SREBP-1d transcript was 
detected in most of normal tissues and also in tumor-derived cells examined 
at different detectable levels. The highest expression was in liver and testis, 
and in lung carcinoma (LX-1 and GI-117) in the tumor-derived cells. On the 
other hand, the SREBP-1f splice variant was detected only in peripheral blood 
leukocyte on a exceptionally low expression level. Furthermore, the analysis 
showed wild-type SREBP-1c transcript at low expression level in placenta, 
liver, spleen, thymus and peripheral blood leukocyte and in all tumor-derived 
cells except prostatic and pancreatic adenocarcinoma (PC3 and GI-103, 
respectively). In contrast to SREBP-1e, the expression of SREBP-1d, 
SREBP-1c and SREBP-1f in tissues and tumor-derived cells appeared to be 
relatively low.  
To summarize our results, the distribution pattern of human SREBP-1 splice 
variants is different in normal tissues and tumor-derived cells. We therefore 
assumed that the expression of these isoforms is regulated by distinct 
mechanisms. 
 
III.2.3. Different ways of induction the SREBP-1 isoforms in HepG2 cells 
 
Recently it has been reported that several compounds (for example 
glucocorticoids) can change the expression level of the splice variants of the 
diacylglycerol kinase (Klauck et al., 1996; Murakami et al., 2003). Based on 
these findings we decided to investigate the possible induction of certain 
drugs, which affect SREBP-1c expression, on the expression pattern of 
SREBP-1 splice variants. HepG2 cells were selected for these experiments, 
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because these cells retain many properties of the hepatocytes from which 
they are derived (Knowles et al., 1980). Simvastatin, a HMG-CoA reductase 
inhibitor and SREBP pathway activator (Brown and Goldstein, 1997), was 
used in this study. Additionally, the HIV-protease inhibitor indinavir, which is 
associated with decreased SREBP-1c expression (Miserez et al., 2002a) and 
finally, insulin, a potent inductor of SREBP-1c gene expression (Foretz et al., 
1999; Shimomura et al.,1999) were tested. 
HepG2 cells were grown in medium supplemented with 10% FBS. The cells 
were treated with 30 µM active dihydroxy-open form of simvastatin, 20 µM  
indinavir and 1 µM insulin for 24 hours. For conditions with low lipid 
concentration, the cells were maintained in medium containing 5% LPDS. 
After RT-PCR using the SREBP-1c-specific primers spanning the exon 17 
and 3’-untranslated region, we found that all splice variants of SREBP-1 could 
be detected at different expression levels (Figure 17). 
 
 
 
Figure 17. Expression regulation of the SREBP-1 splice variants by simvastatin, 
indinavir, insulin and LPDS medium. 1, HepG2 cells were maintained in 10% FCS 
medium and served as a control. 2, HepG2 cells were maintained in 5% LPDS 
medium. 3, HepG2 cells were treated with 30 µM of simvastatin. 4, HepG2 cells were 
treated with 20 µM indinavir. 5, HepG2 cells were treated with 1 µM insulin. The cells 
were incubated for 24 h. Total RNA was isolated and the aliquots (5 µg) were 
subjected to RT-PCR using the SREBP-1c-specific primers spanning the exon 17 
and 3’-untranslated region (F ex17 primer and R 3’UTR primer, respectively). An 
upper panel shows 392 bp, 338 bp, 280 bp and 226 bp DNA fragments amplified for 
SREBP-1e (35 cycles), SREBP-1d (35 cycles), SREBP-1c (35 cycles) and SREBP-1f 
(35 cycles), respectively, in agarose gel electrophoresis. The lower panels exhibit 
261 bp cDNA fragments amplified for human glyceraldehyde phosphate 
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dehydrogenase (GAPDH, 25 cycles). C, control (no template). M, DNA molecular 
weight marker V (Roche Diagnostics). 
 
When HepG2 cells were grown in conditions with low lipid concentration 
(LPDS medium), the level of SREBP-1e mRNA was markedly increased 
(Figure 17). When HepG2 cells were treated with 20 µM of indinavir for 24 h, 
the level of SREBP-1e mRNA was also increased. In contrast, the SREBP-1d 
mRNA was moderately decreased. The splice variants SREBP-1d and 
SREBP-1e were induced by treating cells with 1 µM insulin. Interestingly, 
when HepG2 cells were treated with simvastatin (30 µM), the mRNA level of 
all SREBP-1 variants was markedly decreased (Figure 17). The mRNA level 
of SREBP-1c and SREBP-1f were altered weaker by changing of conditions 
or adding substances. 
The results collectively demonstrated that the expression pattern of mRNA of 
SREBP-1 splice variants were clearly different from each other after addition 
of certain drugs (simvastatin, indinavir, insulin), that affect the SREBP-1c 
expression, or changing the lipid concentration (medium with low lipid level).  
 
III.2.4. Establishment of the stable T-REx-293 cell lines permitting 
inducible expression of wild-type SREBP-1c and the splice variant 
SREBP-1d  
 
As it has been outlined before both, SREBP-1a and -1c, isoforms are derived 
from a single gene through the use of alternative splicing at both, the 5’ and 
the 3’, ends of the mRNA. Exons 1a and 1c are transcribed from different 
promoters using two alternative transcription start sites and spliced to a 
common exon 2 (Figure 4). The new splice variant SREBP-1d was detected in 
the liver cDNA library. This isoform contained exons 17, 18a and 18c at the 3’-
end of mRNA. To investigate the 5’-end of this transcript the polymerase 
chain reaction was performed using two forward primers homologous to exon 
1a and exon 1c, and reverse primer homologous to exon 2 which is specific 
for SREBP-1a and SREBP-1c. This analysis revealed that the amplification 
occurs only when the forward primer, homologous to exon 1c of SREBP-1c 
isoform, was used. Therefore, the splice variant SREBP-1d contains at the 5’-
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end the exon 1c, and the N-terminus of this isoform is similar to the SREBP-
1c. This finding is particularly important because it has been demonstrated 
that the SREBP-1c (not SREBP-1a) predominate in the liver and most other 
intact tissues (Shimomura et al., 1997a). Thus, the 3’-end of coding 
sequences with the entire untranslated region of SREBP-1 from human liver 
cDNA library was cloned into expression plasmid pcDNA4/TO-SREBP-1c 
yielding the expression plasmid pcDNA4/TO-SREBP-1d.  
The T-REx-293 cells, which stably express the tetracycline (Tet) repressor, 
were transfected with the expression vector, pcDNA4/TO, carrying the wild-
type SREBP-1c or the splice variant SREBP-1d. Two-round stable 
transfection experiments were performed, and several zeocin-resistant clones 
selected. The clones were screened for the SREBP-1 expression by culturing 
the cells in medium in the presence or absence of tetracycline (1 µg/ml). RNA 
and cDNA were prepared and analyzed by semi-quantitative RT-PCR for 
induction of SREBP-1c and SREBP-1d expression as described in Materials 
and Methods. The cell line stably transfected with the pcDNA4/TO vector was 
used as control for tetracycline induction of SREBP-1. After screening by 
semi-quantitative RT-PCR for induction of SREBPs we established zeocin-
resistant clones which positively express the transgenes (Figure 18).  
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Figure 18. Induction of wild-type SREBP-1c and the splice variant SREBP-1d after 
tetracycline treatment in T-REx-293 cells. T-REx-293 cells, stably transfected with 
the indicated expression constructs, were treated for 16 hours with tetracycline (1 
µg/ml). The cell line stably transfected with the pcDNA4/TO vector was used as a 
control for tetracycline induction of SREBP-1. Total RNA (5 µg) was used to prepare 
cDNA by reverse transcription with random hexamers primers followed by a semi-
quantitative RT-PCR using the primers specific for SREBP-1c exon 17 and 3’UTR 
(A) and the internal control GAPDH (B) as indicated. PCR products were resolved by 
electrophoresis on a 2% agarose gel containing ethidium bromide. M, DNA molecular 
weight marker V (Roche Diagnostics). C, control (no template). 
 
These clones, termed SREBP-1c and SREBP-1d, which actually represented 
almost undetectable background expression under non-induced conditions, 
showed remarkable expression of SREBPs mRNA after tetracycline induction 
(Figure 18). 
 
III.2.5. Characterization of splice variant SREBP-1d in stably transfected 
T-REx-293 cells by transient transfection of luciferase reporter 
constructs 
 
Two luciferase reporter constructs containing the promoter region of fatty acid 
synthase gene (pGL2-FAS) and lipoprotein lipase gene (pGL2-LPL) were 
used for characterization of the SREBP-1 stable transformants in T-REx-293 
cells. Each luciferase reporter construct was transfected into T-REx-293 cell 
lines stably expressing either wild-type SREBP-1c or the splice variant 
SREBP-1d. After transfection, the cells were incubated with tetracycline (1 
µg/ml) for induction of wild-type SREBP-1c and the splice variant SREBP-1d. 
The cell line stably transfected only with pcDNA4/TO vector was used as 
control for tetracycline induction of endogenous SREBP-1c. After induction of 
SREBPs, cells were treated with 25-hydroxycholesterol and cholesterol as a 
control of the inhibition of the SREBP-regulated reporter genes; and with the 
dihydroxy-open form of simvastatin as a control of the activation of the 
SREBP-regulated reporter genes.  
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Figure 19 compares the ability of wild-type SREBP-1c and the splice variant 
SREBP-1d to induce transcription of the FAS and LPL luciferase reporter 
genes. Both, wild-type SREBP-1c and the splice variant SREBP-1d, 
transformants exhibit relatively strong transactivation of the transiently 
transfected reporters constructs in comparison with a control cell line stably 
transfected with the pcDNA4/TO expression vector. As shown in Figure 19, 
wild-type SREBP-1c produced a transcriptional response that was 
significantly larger than the splice variant SREBP-1d when simvastatin, a 
SREBPs agonist, was added to the culture medium. 
 
 
 
Figure 19. Characterization of the SREBP-1d stable transformant by transient 
transfection of luciferase reporter constructs. The luciferase reporter constructs 
containing the promoter region of fatty acid synthase (pGL2-FAS) and lipoprotein 
lipase (pGL2-LPL) were co-transfected with the pRL-CMV vector containing Renilla 
luciferase into T-REx cell lines, stably expressing either wild-type SREBP-1c or the 
splice variant SREBP-1d. The cell line stably transfected with the pcDNA4/TO vector 
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was used as control for tetracycline induction of endogenous SREBP-1. The sells 
were treated with 25-hydroxycholesterol (1 µg/ml) and cholesterol (10 µg/ml) (Sigma) 
as a control of the inhibition of the SREBP-regulated reporter genes; and with the 
dihydroxy-open form of simvastatin at final concentrations of 1x104, 2x104 and 3x104 
nmol/l as a control of the activation of the SREBP-regulated reporter genes. For all 
transfections, activation of luciferase was corrected for transfection efficiency with 
Renilla luciferase activity levels, and all data are represented accordingly as relative 
light units. A. Luciferase activity is expressed as the -fold increase relative to 
untreated (without simvastatin) control T-REx cells stably transfected with the 
pcDNA4/TO vector. B. Comparison of maximum activation of FAS and LPL reporter 
genes by simvastatin (30 µM) in T-REx cells stably expressing either wild-type 
SREBP-1c (grey) or SREBP-1d (black). Luciferase activity of control T-REx cell line 
was subtracted to luciferase activity of cell lines stably transfected with wild-type 
SREBP-1c and SREBP-1d. The error bars indicate S.D. from the mean. *, P = 0.002 
(comparison between wild-type SREBP-1c and SREBP-1d for FAS gene); P = 0.05 
(comparison between wild-type SREBP-1c and SREBP-1d for LPL). 
 
It is important to notice, that expression of SREBP-1d even at low levels was 
sufficient to cause cell toxicity as observed by morphological changes of the 
cells. After induction of the stably transfected SREBP-1d splice variant with 
tetracycline for 16 hours, the cell toxicity was detected microscopically based 
on morphological alterations typical for adherent cells undergoing apoptosis, 
including becoming rounded, condensed, and detached from the dish. On the 
other hand, the cell toxicity was not detected in the cell line that was stably 
transfected with wild-type SREBP-1c after induction of expression of this 
isoform with tetracycline. This finding prompted us to assume that cell toxicity 
after induction of the splice variant SREBP-1d versus wild-type is dependent 
on differences exclusively in the last exons of the 3’ terminus. 
 
III.2.6. Differences of the mRNA stability of wild-type SREBP-1c and the 
splice variant SREBP-1d 
 
For analysis of the SREBP-1d mRNA stability, T-REx-293 cells, stably 
transfected with wild-type SREBP-1c and the splice variant SREBP-1d, were 
cultured in the presence of tetracycline (1 µg/ml) for induction of these 
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isoforms. Transcription was then inhibited by the addition of actinomycin D. 
Actinomycin D was added to the growth medium (5 µg/ml), and the cells were 
incubated for the indicated time (Figure 20). Total cellular RNA from stably 
transfected cells was isolated. cDNA was used as a template for the 
quantitative polymerase chain reaction analysis based on the 5'-nuclease 
assay with the ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems). Figure 20 demonstrates that mRNA of the splice variant 
SREBP-1d is more stable than wild-type SREBP-1c mRNA (P = 0.001). 
These data suggest that the exons differences in the coding 3’-end of the 
SREBP-1 gene affects the secondary structure of the SREBP-1 mRNA and 
influence its degradation rate. 
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Figure 20. The mRNA stability of wild-type SREBP-1c and alternative splice variant 
SREBP-1d. T-REx-293 cells stably transfected with indicated expression constructs 
were treated for 16 hours with tetracycline (1 µg/ml). Than actinomycin D was added 
(5 µg/ml) and total cellular RNA was harvested after an additional 1, 2, 4, 6 or 8 
hours. The SREBP-1 mRNA levels were evaluated with a real time quantitative 
polymerase chain reaction method as described in Materials and Methods. The error 
bars indicate S.D. from the mean. The graph depicts the % mRNA remaining after 8 
h of actinomycin D. 
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IV. Discussion 
 
IV.1. The role of SREBP-1c in drug induced hyperlipidemia 
 
IV.1.1. The effects of HIV-protease inhibitor indinavir on SREBP-1c 
 
In the present study, the influence of indinavir on the activation of effector 
genes involved in the triglyceride, cholesterol, and insulin metabolism was 
investigated.  
The major findings were that indinavir (i) decreased the activities of the 
SREBP-1c/ADD-1-dependent LPL and FAS reporter genes in a dose-
dependent manner and (ii) did not decrease the activity of the SREBP-
1c/ADD-1-independent LDLR reporter gene. 
Inhibition of the LPL and FAS reporter gene activities was detectable starting 
from an indinavir concentration of 10–1 nmol/l (LPL) or 10–2 nmol/l (FAS). For 
comparison: concentrations of 5 × 101 to 102 nmol/l indinavir inhibit viral 
spread by 95% in cell culture (Vacca et al., 1994), concentrations of 102-103 
nmol/l indinavir correspond to physiological mean plasma concentrations in 
patients on treatment, and concentrations of 103-105 nmol/l correspond to 
mean plasma concentrations usually not achieved in the steady state 
(Indinavir Sulfat. Merck, Sharp & Dohme; 1998). Since we observed clear 
decreases (12.4% for LPL and 30.3% for FAS) at an indinavir concentration of 
103 nmol/l, we expect that administration of indinavir in recommended doses 
(2.4 g daily) will result in changes in the expressions of the LPL and FAS 
genes in vivo as well. In contrast, a significant inhibition of the LDLR reporter 
gene activity was not detectable, even at an indinavir concentration of 2 × 104 
nmol/l. This result was not unexpected. We previously hypothesized that the 
pathophysiological mechanism to induce the hypertriglyceridemia, 
hypercholesterolemia, hyperinsulinemia, and lipodystrophy syndrome 
observed in HIV-infected patients is mediated by the SREBP-1c/ADD-1 
pathway rather than by the SREBP-2 pathway (Miserez et al., 2001). Since 
the gene encoding the LDLR is activated by SREBP-2 but much less by 
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SREBP-1c/ADD-1 (Shimano et al., 1997a), the lack of a significant inhibition 
of the LDLR reporter gene activity by indinavir is in line with our hypothesis. 
Using other experimental approaches, PI have been shown to inhibit SREBP-
1c/ADD-1 (Caron et al., 2001), insulin-stimulated glucose uptake (Murata et 
al., 2000), insulin signalling (Caron et al., 2001; Schütt et al., 2000) and 
adipocyte determination and differentiation (Caron et al., 2001; Zhang et al., 
1999; Wentworth et al., 2000), and to induce adipocyte apoptosis (Domingo et 
al., 1999) and modulate proteosome activity (Schmidtke et al., 1999). In 
particular, the results of Caron et al. demonstrated a clear indinavir-induced 
impairment of SREBP-1 (Caron et al., 2001). Caron et al. focused on the 
indinavir-induced inhibition of insulin effects and adipocyte determination and 
differentiation, which are both mediated by SREBP-1c/ADD-1. Our results 
demonstrate the indinavir-induced inhibition of the lipoprotein and fatty acid 
metabolism, both also mediated by SREBP-1c/ADD-1, and are, therefore, in 
agreement with the observations of these authors. Thus, the indinavir-induced 
inhibition of effector genes regulated by SREBP-1c/ADD-1 can lead to 
hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia and 
lipodystrophy: the syndrome observed in HIV-infected patients on ART. 
SREBP-1c/ADD-1 plays a central role in the regulation of triglycerides, 
cholesterol, insulin, and adipose tissue formation. Administration of PIs, 
associated with hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia 
and peripheral lipodystrophy, affects SREBP-1c/ADD-1 and, therefore 
SREBP-1c/ADD-1-dependent effector genes. SREBP-1c/ADD-1 specifically 
activates the genes encoding the LPL and FAS (Schoonjans et al., 2000; 
Bennett et al., 1995; Xiong et al., 2000; Magaña et al., 2000) as well as the 
adipocyte determination and differentiation (Tontonoz et al., 1993). 
SREBP-1c/ADD-1 controls the peripheral clearance of triglyceride- and 
cholesterol-rich lipoproteins via regulation of LPL (Shimomura et al., 1998; 
Kim and Spiegelman, 1996; Shimano et al., 1996). Inhibition of LPL results in 
hypertriglyceridemia and hypercholesterolemia (Figure 21), as observed in 
inherited LPL deficiency syndromes (Figure 21) (Yang et al., 1995; 
Reynisdottir et al., 1995; Ishimura-Oka et al., 1992). SREBP-1c/ADD-1 
controls fatty acid synthesis via regulation of FAS (Bennett et al., 1995; 
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Magaña et al., 2000) and the determination and differentiation of adipocytes 
(Tontonoz et al., 1993; Kim and Spiegelman, 1996). SREBP-1c/ADD-1 
controls the insulin effect via regulation of a series of genes such as those 
encoding LPL (Schoonjans et al., 2000), FAS (Bennett et al., 1995; Magaña et 
al., 2000), and glucokinase (Foretz et al., 1999) (Figure 21). Inhibition of these 
genes results in a decreased insulin effect and, thus, insulin resistance 
(Foretz et al., 1999; Sul et al., 2000). Plasma insulin then increases in 
compensation (Flier and Hollenberg, 1999). Consequently, inhibition of LPL, 
FAS and the gene encoding the glucokinase results in hyperinsulinemia. The 
proof of this concept is inherited defects affecting, for example, the genes 
encoding LPL (Yang et al., 1995; Reynisdottir et al., 1995; Ishimura-Oka et 
al., 1992) and glucokinase (Froguel et al., 1993) (Figure 21). In line with these 
observations are our previous findings of a significant and parallel increase in 
plasma cholesterol and plasma insulin levels in HIV-1-infected subjects 
treated with PIs (Miserez et al., 2001). 
 
 
 
Figure 21. Protease inhibitor-induced changes in the sterol-regulatory element-
binding protein-1c/adipocyte determination and differentiation factor-1c (SREBP-
1c/ADD-1)-regulated pathway. SREBP-1c/ADD-1 controls the genes encoding the 
lipoprotein lipase (LPS), fatty acid synthase (FAS) and the glucokinase as well as the 
adipocyte determination and differentiation. In subjects treated with antiretroviral 
therapy (ART), inhibition of the SREBP-1c/ADD-1-mediated LPL activity is expected 
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to result in a combined hyperlipoproteinemia (increases in triglycerides and 
cholesterol) similar to that observed in LPL deficiency syndromes (Yang et al., 1995; 
Reynisdottir et al., 1995; Ishimura-Oka et al., 1992). Inhibition of SREBP-1c/ADD-1-
mediated FAS activity is expected to result in a decrease in fatty acids and in an 
increase in insulin (Zhang et al., 1999; Wentworth et al., 2000). SREBP-1c/ADD-1 is 
regulated by insulin (Flier et al., 1999; Streicher et al., 1996; Shimomura et al., 1999) 
and has an insulin-mimicking effect (Foretz et al., 1999). Inhibition of SREBP-
1c/ADD-1, therefore, results in decreased activity of various insulin-dependent genes 
(including the gene for glucose 6-phosphate; (Foretz et al., 1999; Flier and 
Hollenberg, 1999) and, hence, in reactive hyperinsulinemia. In ART-treated subjects, 
inhibition of SREBP-1c/ADD-1-mediated adipocyte determination and differentiation 
alters peripheral adipose tissue directly and may, therefore, contribute to ART-related 
peripheral lipodystrophy (Caron et al., 2001; Zhang et al., 1999; Wentworth et al., 
2000).  
 
Inhibition of fatty acid synthesis and adipocyte determination and 
differentiation results in decreased fatty acid synthesis and adipose tissue 
formation (Caron et al., 2001; Zhang et al., 1999; Wentworth et al., 2000) and 
might therefore explain particular aspects of peripheral lipodystrophy in 
humans (Figure 21). The mechanisms causing lipoatrophy however might 
rather be caused by additional pathways (TNF-, PPAR-) (Bastard et al., 
2002; Kannisto et al., 2003). 
Proteolytic cleavage of SREBP-2 activates the gene encoding the LDLR 
strongly whereas proteolytic cleavage of SREBP-1c/ADD-1 activates LDLR 
much less (Shimano et al., 1997a). Similarly, simvastatin activates the 
SREBP-2-dependent LDLR gene strongly (approximately 500%, Fig. 8C) but 
activates the SREBP-1c/ADD-1-dependent LPL and FAS genes much less 
(approximately 100%, Fig. 8 A, B). Inhibition of the SREBP-2-dependent 
LDLR gene (as in familial hypercholesterolemia caused by LDLR gene 
defects) results in hypercholesterolemia but in most cases (90%) not in a 
hypertriglyceridemia (Brown and Goldstein, 1997). In ART-associated 
hyperlipidemia, however, hypertriglyceridemia is the predominant phenotype. 
In line with this latter observation, in our cell culture experiments, indinavir 
inhibited LDLR much less, indicating that the SREBP-1c/ADD-1-mediated 
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mechanisms play the predominant role in the development of ART-associated 
adverse effects. 
We previously cloned and characterized the promoters of the differentially 
spliced genes of SREBP-1, SREBP-1a and SREBP-1c/ADD-1 and 
characterized the SREBP-2 gene (Miserez et al., 1997). Very recently, we 
identified in the gene encoding SREBP-1c/ADD-1 a marker predictive of the 
hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia and 
lipodystrophy syndrome (Miserez et al., 2001). Although, in our experience, 
other cell lines such as HepG2 cells are more difficult to transfect than 
HEK293 cells, analogous experiments carried out using HepG2 cells instead 
of HEK293 cells resulted in similar inhibitory effects on FAS gene activation. 
Hence, there is strong evidence from others (Dowell et al., 2000; Caron et al., 
2001) as well as from our own previous (Miserez et al., 2001) and present 
results that inhibition of SREBP-1c/ADD-1 is involved in the development of 
the ART-related hyperlipidemia, hyperinsulinemia, and lipodystrophy 
syndrome. Nevertheless, it remains to be clarified how PIs mediate the 
inhibition of SREBP-1c/ADD-1. The HIV-1 protease (GenBank 230883) and 
the site-1 protease (GenBank 4506775), a sterol-regulated protease that 
cleaves the SREBP molecules (Sakai et al., 1998), share a sequence 
homology at their catalytic sites. Despite this sequence homology, the HIV-1 
protease and the site-1 protease belong to different classes of proteases. 
Therefore, because of considerable differences in the three-dimensional 
structures of the HIV-1 protease and the site-1 protease and based on steric 
models, it is unlikely that PI influence the SREBP pathway by direct inhibition 
of the site-1 protease. Similarly, these considerations apply to the hypothesis 
that PIs interact with the adipocyte-enhancer binding protein (Gagnon et al., 
1998). Furthermore, if the site-1 protease was inhibited, we would expect 
quantitatively similar effects regarding the impairment of the activation of 
SREBP-1c/ADD-1- and SREBP-2-dependent genes. However, this was 
clearly not the case in our experiments. 
A possible explanation for the differential inhibition of SREBP-1c/ADD-1- and 
SREBP-2-dependent genes is based on recent experiments suggesting 
differences in the regulation of the amount of mature SREBP-1c/ADD-1 and 
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SREBP-2. While SREBP-1c/ADD-1 is controlled by two independent 
mechanisms, by cleavage activation and by the rate of mRNA degradation 
(Xu et al., 1999), there is no evidence that SREBP-2 is regulated by the latter 
(Brown and Goldstein, 1997). 
In summary, our demonstration of the inhibition of SREBP-1c/ADD-1-
dependent genes explains the major metabolic effects described in 
association with ART. 
 
IV.1.2. The role of single-nucleotide polymorphism in SREBP-1c gene in 
protease inhibitor-induced hyperlipoproteinemia 
 
Inhibition of SREBP-1c-dependent genes by protease inhibitors such as 
indinavir explains the major metabolic effects associated with ART and 
demonstrates the crucial role of SREBP-1c in these metabolic pathways. A 
variant in the gene encoding SREBP-1c, the SREBP-1c-3’322C/G variant, 
was discovered as a pharmacogenetic marker that is predictive of HIV-PIs 
induced metabolic disturbances. Increases in cholesterol, triglycerides and 
insulin were less frequently associated with homozygous SREBP-1c-3’322G 
(genotype 22) than with heterozygous/homozygous SREBP-1c-3’322C 
(genotypes 11/12) (Miserez et al., 2001).  
To investigate the molecular basis of these SNP-associated differences, we 
first excluded the possibility that SREBP-1c-3’322G causes alternative 
splicing. Silent polymorphisms/mutations (i.e. those that do not change the 
amino acid sequence, such as SREBP-1c-3’322C/G) may lead to alternatively 
spliced transcripts by disruption of exonic splicing enhancers (ESE) or 
activation of cryptic splicing sites and thus affect the correct splicing pattern 
(Maniatis and Tasik, 2002; Nissim-Rafinia and Kerem, 2002). We did not find 
an association between the new discovered alternative splicing of SREBP-1 
at the 3’ end of mRNA and the single-nucleotide polymorphism 3’322C/G in 
exon 18c. 
Furthermore, synonymous mutations, such as SREBP-1c-3’322C/G, cannot 
be a priori considered as neutral or non-pathogenic, because they may 
directly affect mRNA structure and/or stability (Richard and Beckmann, 1995). 
The computer-based analyses was used to predict differences in the putative 
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mRNA secondary structure (SREBP-1c-3’322C versus SREBP-1c-3’322G). 
The analyses revealed conformational differences of SREBP-1c-3’322C/G 
isoforms at the mRNA level. This finding is particularly important because it 
has been demonstrated that the SREBP-1c pathway is regulated at the 
mRNA level additionally (Xu et al., 1999; Xu et al., 2001). As the expression of 
SREBP-1c gene can be regulated at the mRNA level, we supposed that 
another specific sequence variation (3’322C/G SNP) could affect the 
secondary structure of the SREBP-1c mRNA and influence its degradation 
rate additionally. A possible association between the mRNA stability of the 
SREBP-1c gene in the presence of a single-nucleotide polymorphism 
3’322C/G was determined in vitro.  
As it has been outlined before, the cells express two forms of SREBP-1, 
SREBP-1a and -1c. The SREBP-1 antibody recognizes both proteins. 
Consequently, the relative abundance of the two proteins cannot be differently 
quantified using Western blotting. Therefore, we compared the SREBP-1c 
mRNA stability of both homozygous genotypes using a real time quantitative 
polymerase chain reaction method using primers specific exclusively for the 
SREBP-1c isoform. For this study, the T-REx-293 System, a Tetracycline 
Regulated mammalian Expression System, was used. After having performed 
the stable transfection, stable cells lines were obtained which stably and 
inducibly expressed wild-type SREBP-1c (genotype 11) and SREBP-1c 
3’322C/G (genotype 22). These stable cell lines provided an unique 
opportunity to study the influence of SREBP-1c SNP 3’322C/G on mRNA 
stability and to explain the changes in lipid metabolism in HIV patients after 
PIs treatment. Our results indicated that mRNA of the SREBP-1c-3’322G 
(genotype 22) was more stable than wild-type SREBP-1c-3’322C (genotype 
11) mRNA. SREBP-1c-3’322C/G mRNA has a half-life of about 6 hours, 
whereas wild-type SREBP-1c has a half-life of about 3.5 hours. These data 
suggest that sequence differences in the coding 3’-end of the SREBP-1c gene 
(3’322C/G SNP) affect the secondary structure of the SREBP-1c mRNA and 
influence its degradation rate. 
A striking observation was that the cell line which was stably transfected with 
SREBP-1c isoform contained the single-nucleotide polymorphism 3’322C/G 
activated SREBP-1c-dependent FAS and LPL reporter genes to a larger 
Discussion 
77 
extend than the cell line which was stably transfected with wild-type SREBP-
1c isoform. Furthermore, these observations are in line with the SREBP-1c 
mRNA stability results obtained from real-time quantitative PCR experiments. 
The differences in genotype-specific SREBP-1c mRNA stability cause, 
therefore, the expression differences in the SREBP-1c-dependent genes. 
Thus, the molecular mechanism of the 3’322C/G SNP-associated differences 
could be explained with different decay rates of both SREBP-1c mRNAs. A 
lower stability of SREBP-1c wild-type mRNA would result in an accelerated 
mRNA degradation and a weaker SREBP-1c activation. Hence, SREBP-1c 
would then be less active in presence of PIs in genotype CC/GG-carriers 
(genotypes 11/12) than in genotype GG-carriers (genotype 22). In the case of 
the wild-type SREBP-1c-3’322C isoform (genotype 11), fewer precursor 
molecules are cleaved and fewer mature transcription factor molecules enter 
the nucleus. This leads to a decrease in the activation of FAS, LPL and 
glucokinase genes. As a consequence, the cholesterol and triglyceride uptake 
from the plasma, fatty acid synthesis and insulin effects decrease. 
Subsequently, plasma total cholesterol, triglyceride, and insulin 
concentrations increase causing hypercholesterolemia, hypertriglyceridemia, 
and hyperinsulinemia in heterozygous/homozygous SREBP-1c-3'322C 
(genotypes 11/12) HIV-infected subjects after PIs treatment. 
In summary, it has been demonstrated that sequence differences in the 
coding 3’-end of the gene (3’322C/G SNP) affect the secondary structure of 
the SREBP-1c mRNA, influence its degradation rate and, therefore, cause 
differences in the regulation of SREBP-1c expression. 
 
IV.2. Alternative splicing of human SREBP-1 
 
In the present study, we showed for the first time that there exist further 
functionally important splice variants of the human SREBP-1 gene. The new 
alternative splicing occurs at the 3’ end of human SREBP-1 pre-mRNA and 
generates isoforms with large diversity of structure and function. 
The resulting isoforms were different in the COOH-terminal domain of 
SREBP-1. It is important to notice that this COOH-terminal region performs 
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the essential regulatory function of the SREBPs (Brown and Goldstein, 1997). 
As it has been previously demonstrated, the newly synthesized SREBP is 
inserted into the membranes of the ER, where its COOH-terminal regulatory 
domain binds to the COOH-terminal domain of SCAP (SREBP cleavage 
activator protein). SCAP is both an escort protein for the SREBPs and a 
sensor of the intracellular sterol concentration. When cells are depleted of 
cholesterol, SCAP escorts the SREBP from the ER to the Golgi apparatus, 
where the SREBPs are cleaved. The N-terminal part of SREBP enters the 
nucleus and binds to sterol regulatory elements (SREs) in the promoters of 
genes encoding the enzymes of cholesterol and fatty acid biosynthesis 
(Brown and Goldstein, 1997; Horton et al., 2002). Truncation of SREBP at its 
COOH-terminus prevents the formation of complexes with SCAP and 
simultaneously reduces proteolytic cleavage (Sakai et al., 1997). Furthermore, 
the cytoplasmic COOH-terminal domain of the SREBP is required that the 
Site-1 enzyme can be active. When this domain in SREBP is shortened 
through truncation mutations, cleavage by the Site-1 protease is abolished 
(Ericsson et al., 1996). In this context it is important to notify that the new 
discovered alternative splicing changes the tertiary structure of the SREBP-1, 
especially the conformation of the COOH-terminus. It could play some 
functional role in such a way that the SCAP/SREBP complex formation, 
transport to the Golgi, cleavage (Site-1 protease) and, therefore, the release 
of active mature N-terminus isoform could be affected. As a result, the 
regulation of downstream genes of SREBP-1 (fatty acid synthase, lipoprotein 
lipase, glucokinase) and, subsequently, the metabolism of cholesterol, 
triglyceride, fatty acid, glucose, and insulin could be influenced. 
In the splice variant SREBP-1c, exons 1, 18, and 19 are different from 
SREBP-1a (Hua et al., 1995), leading to dramatically different biological 
properties of SREBP-1c versus SREBP-1a (Shimano et al., 1997a). Cleavage 
of SREBP-1a protein, containing exons 18a and 19a in the COOH-terminal 
region, is completely suppressed by sterol overloading. However, in contrast, 
cleavage of SREBP-1c is not regulated by sterols (Hua et al., 1996). This 
finding was a surprise, and is very likely to have important physiologic 
implications. Sequences less important for regulation were traced back to two 
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exons of the COOH-terminal domain: 18a19a and 18c19c. An interesting 
finding is that the newly discovered alternative splicing event occurs exactly 
between these two exons. It may therefore influence the regulation of SREBP-
1 (for example the sensibility to sterols) or the functional consequences of 
different splice isoforms. 
In this context, it is important to mention that inducible expression of the splice 
variant SREBP-1d even at low levels was sufficient to cause cell toxicity as 
observed by morphological changes of the cells. On the other hand, the cell 
toxicity was not detected in the cell line that was stably transfected with wild-
type SREBP-1c after induction of expression of this isoform with tetracycline. 
This finding prompted us to assume that cell toxicity after induction of the 
splice variant SREBP-1d versus wild-type is dependent on differences 
exclusively in the last exons of the 3’ terminus. 
Based on the observation that cell toxicity was detected after induction of the 
splice variant SREBP-1d only and not after induction of the wild-type SREBP-
1c, we could explain a low level of expression of fatty acid synthase (FAS) 
and lipoprotein lipase (LPL) effector genes in the T-REx-293 cells stably 
transfected with the SREBP-1d isoform (Figure 19). Interestingly, after 
normalization to unstimulated cells, we observed an activation of FAS and 
LPL reporter genes by splice variant SREBP-1d larger than wild-type SREBP-
1c. Additionally, the mRNA stability experiments in stably transfected T-REx-
293 cells demonstrated that the mRNA of the splice variant SREBP-1d is 
more stable than the mRNA of wild-type SREBP-1c (Figure 20). This would 
cause an overexpression of the splice variant SREBP-1d and therefore an 
overexpression of lipogenic genes. It has been demonstrated in several 
animal models of diabetes that expression of SREBP-1c is increased in liver 
(Shimomura et al., 1999a; Kakuma et al., 2000). Overexpression of SREBP-1 
has been suggested to be the cause of this kind of hepatic steatosis 
(Shimomura et al., 1999a; You et al., 2002). Furthermore, cell toxicity after 
expression of the nuclear active form of SREBP-1c (only N-terminus) was 
observed in insulinoma INS-1 cells (Wang et al., 2003). These results 
demonstrated that induction of the nuclear active form SREBP-1c leads also 
to INS-1 cells growth arrest and apoptosis (Wang et al., 2003). 
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Nonsense-mediated mRNA decay (NMD), is a mechanism by which cells can 
eliminate imperfect mRNAs, which would lead to the translation of potentially 
harmful or toxic proteins (Maquat, 1995). Nonsense and frameshift mutations 
introduce premature translation termination codons (PTCs) into the open 
reading frames (ORFs) of the affected mRNAs and are common causes of 
genetic disorders. The hallmark of NMD has been the reduction in abundance 
of the mRNA associated with a premature termination codon. Elimination of 
frameshifted mRNAs that result from cryptic splicing events is therefore likely 
to represent an important function of NMD in thalassemia and other genetic 
disorders (Danckwardt et al., 2002; Perrin-Vidoz et al., 2002). It should be 
mentioned that only one splice variant (SREBP-1e) could be appropriate to 
the mechanism of the nonsense-mediated mRNA decay. In mammals, a stop 
codon is recognized as a premature termination codon only when followed by 
an intron (Li and Wilkinson, 1998). Not all mRNAs that contain PTCs are 
target for destruction. As a general rule, only mammalian transcripts that 
contain a nonsense codon more than about 50 nucleotides upstream of the 
last exon-exon junction will be subjected to NMD (Zhang et al., 1998). 
Accordingly, the vast majority of mammalian genes contain the termination 
codon in the last exon or <50 nucleotides upstream of the last intron (Nagy 
and Maquat, 1998). This suggests that the nonsense-mediated mRNA decay 
requires an intron in the target mRNA. In the splice variant SREBP-1d a 
premature termination codon is located in exon 18c which followed an 3’ 
untranslated region. This PTC can not be recognized and mRNA can not be 
subjected to NMD. In the case of splice variant SREBP-1e, the premature 
termination codon occurs in exon 18c which is followed by an intron and, 
subsequently, by exon 19c (Figure 14). This premature termination codon 
should be recognized as the trigger of NMD because it is located more than 
50 nucleotides (67 nt) upstream of the intron or the final exon-exon junction. 
Interestingly, the mRNA of this splice variant was detected in the most human 
tissues (Figure 16) and lymphocytes from several patients. The presence of 
mRNA of this splice variant implies that the mutant message can escape 
nonsense-mediated mRNA decay (Perrin-Vidoz et al., 2002; Danckwardt et 
al., 2002) and that a truncated SREBP-1e protein may be produced in the cell. 
Moreover, this finding suggests the existence of additional, unidentified 
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determinants that modulate the NMD sensitivity of these transcripts 
(Danckwardt et al., 2002). 
In the present study we investigated the expression patterns of the new 
SREBP-1 isoforms in different human normal and tumor tissues. Recently 
Shimomura I. et al. investigated the SREBP-1a and -1c expression in different 
human tissues and cultured cells (Shimomura et al., 1997a). They focussed 
on the expression of alternative versions of exon 1 of SREBP-1 only, which 
were designated 1a and 1c, respectively. They found that the 1a exon 
predominates in all cultured cell lines; in contrast, the 1c exon predominates in 
liver, adrenal gland, white adipose tissue, ovary, brain and muscle tissues. 
Because the expression pattern of SREBP-1 at the 5’ end was known 
(Shimomura et al., 1997a), we concentrated on the 3’ end of SREBP-1 
mRNA. Surprisingly, SREBP-1c, -1d, -1e and -1f isoforms were expressed 
differently in various tissues. The alternatively spliced SREBP-1e transcript 
was expressed in all normal tissues and tumor-derived cells at different levels. 
The highest expression levels were detected in liver, placenta, pancreas, 
testis, thymus and prostate tissues, and in lung carcinoma (LX-1 and GI-117), 
colon adenocarcinoma (CX-1 and GI-112) and ovarian carcinoma (GI-102) in 
the tumor-derived cells. The SREBP-1d transcript was detected in most of the 
normal tissues and tumor-derived cells examined at different expression 
levels. The highest expression was detected in liver and testis, and lung 
carcinoma (LX-1 and GI-117) in the tumor-derived cells. On the other hand, 
the SREBP-1f splice variant was detected only in peripheral blood leukocyte 
with a low expression level. The analysis detected wild-type SREBP-1c 
transcript with low expression level in placenta, lung, spleen and thymus, and 
in all tumor-derived cells with exception of prostatic and pancreatic 
adenocarcinoma (PC3 and GI-103, respectively). SREBP-1e and SREBP-1d 
showed a much broader tissue distribution, whereas the expression of 
SREBP-1c and, especially, SREBP-1f were relatively tissue-specific. It is 
important to mention that the splice variant of human SREBP-1c (wild-type) 
which sequence is published in GenBank (AH004383), was isolated from 
cultured HeLa cells (Yokoyama et al., 1993) where this transcript is most 
abundant. Whereas in our study the new splice variants were isolated from 
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human normal tissues and tumor-derived cells where these transcripts, in 
particular SREBP-1d and -1e, were most abundant. This high abundance led 
us to the hypothesis that SREBP-1e and SREBP-1d play a more general role 
in regulating cellular lipid levels as compared to other isoforms. 
Based on the finding of three new isoforms of the SREBP-1 gene, we were 
curious to investigate whether certain drugs, that have an influence on 
SREBP-1c, could induce or suppress their expression. We confirmed that 
upon HepG2 cells stimulation by simvastatin, indinavir, insulin and LPDS 
(conditions with low lipoprotein concentration) the mRNA pattern of SREBP-1 
splice variants was changed. Conditions with low lipids concentration (LPDS 
medium) markedly increased the level of SREBP-1e mRNA. After treatment 
with indinavir the expression of SREBP-1e mRNA was also induced. In 
contrast, the SREBP-1d mRNA was moderately decreased. The splice 
variants SREBP-1d and SREBP-1e were induced by treating cells with insulin. 
Interestingly, when HepG2 cells were treated with the lipid lowering drug 
simvastatin (30 µM), the mRNA level of all SREBP-1 variants was markedly 
decreased (Figure 18). The mRNA expression levels of SREBP-1c and 
SREBP-1f were not much affected by changing of conditions or adding drugs. 
The results collectively demonstrated that the induction pattern of mRNA of 
SREBP-1 splice variants were clearly different from each other after addition 
of certain drugs (simvastatin, indinavir, insulin), that affect the SREBP-1c 
expression, or changing the lipid concentration. Therefore, the choices of the 
splice sites occur in highly inducer-specific manners. However, because of the 
general lack of understanding how cells choose and change particular splice 
sites (Black, 2000), regulatory mechanisms of alternative splicing of the 
SREBP-1 gene are still unclear.  
Our results pointed to the direction that alternative splicing may be a 
mechanism in regulating SREBPs functions in different tissues and cells 
types. The marked divergence of SREBP-1 isoforms elicited by alternative 
splicing may reflect their physiological importance and the needs to respond 
to a variety of signaling pathways operating under distinct regulatory 
mechanisms.
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V.Outlook 
 
The aim of any drug treatment is to achieve the desired effect while having 
few side effects. Genetic differences between individuals can cause 
differences in the efficacy of a particular drug and can contribute to 
unexpected side effects. The sterol-regulatory element-binding protein-1c 
became an interesting candidate gene, based on the pattern of physiological 
processes it regulated and being possibly involved in the pathogenesis of the 
metabolic syndrome. The genetic marker SREBP-1c-3'322C/G is associated 
with hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, and 
lipodystrophy syndrome, which can occur during therapy with antiretroviral 
drugs as part of an antiretroviral treatment (ART), in particular when protease 
inhibitors are used. The pharmacogenetic basis of this finding can be 
explained by the differences in messenger RNA stability of both genotypes 
(SREBP-1c-3’322C versus SREBP-1c-3’322G). Hence, this novel genetic 
marker can be routinely tested before the specific drug is taken and can 
contribute to the optimization of the efficacy and reduction of side effects. 
In addition, a variety of new splice variants of the SREBP-1 gene has been 
described as well as a number of drugs (for example: indinavir, simvastatin) 
on their expression level has been examined. The present study supports the 
hypothesis that the response to a certain drug can alter the splice variant 
pattern of SREBP-1. Furthermore, RNA derived from the lymphocytes of the 
various individuals investigated demonstrated a considerable variety of splice 
variants in different quantities. Based on the fact that different drugs have 
various effects and side effects in different patients, it is important to create 
further tools which: (i) allow the prediction of possible adverse effects of drugs 
in patients by altering their SREBP-1 pattern, and (ii) if there is a side effect of 
a given drug, some patients may be protected from particular adverse effects. 
Further studies could investigate the additional functions of SREBP-1 splice 
variants. Further insights how the SREBP-1 isoforms interact with the signal 
transduction pathways, and how these signals regulate the splicing pattern 
and mRNA stability of these variants are the goal of further research projects.  
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